Repressive RNA targeting C3
By targeting repressive RNA sequences of C3, especially siRNA, the expression of C3 transcripts is inhibited, thus addressing the disease problem caused by complement overactivation. This results in a significant reduction in the levels of C3 protein and transcripts, and can treat a variety of complement-mediated diseases.
Patent Information
- Application Number
- CN202580029181.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-10-25
- Filing Date
- 2025-02-21
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies have failed to effectively inhibit the overactivation of complement C3, leading to the occurrence of various serious diseases and symptoms.
Develop repressive RNA sequences targeting C3, such as siRNA, to suppress the expression of C3 transcripts by complementing them, thereby reducing the levels of C3 protein and transcripts.
It significantly reduces the levels of C3 protein and transcripts, effectively treating or preventing complement-mediated conditions such as paroxysmal nocturnal hemoglobinuria, multiple sclerosis, and membranoproliferative glomerulonephritis, and reducing tissue damage caused by complement activation.
Smart Images

Figure CN123124980A_ABST
Abstract
Description
[0001] Cross-references to related applications This application claims the benefit of U.S. Provisional Application No. 63 / 556,773, filed February 22, 2024; U.S. Provisional Application No. 63 / 649,886, filed May 20, 2024; U.S. Provisional Application No. 63 / 711,985, filed October 25, 2024; and U.S. Provisional Application No. 63 / 711,856, filed October 25, 2024, the contents of each of which are hereby incorporated herein by reference in their entirety. Technical Field
[0002] This disclosure relates to repressive RNA sequences targeting C3, modification patterns, and uses thereof. Background Technology
[0003] The complement system is composed of more than 30 plasma and cell-binding proteins that play a crucial role in both innate and adaptive immunity. The proteins in the complement system function in a series of enzymatic cascades through various protein-protein interactions and cleavage events. Complement activation occurs via three main pathways: the antibody-dependent classical pathway, the alternative pathway, and the mannose-binding lectin (MBL) pathway. Inappropriate or excessive complement activation is a root cause or contributing factor to many serious diseases and conditions. Summary of the Invention
[0004] This disclosure covers repressive RNA sequences targeting C3, such as siRNA, including compositions containing such sequences, and methods of using them.
[0005] In one aspect, this disclosure provides a segregated, modified sequence comprising any one of SEQ ID NO: 15-28. In another aspect, this disclosure provides a segregated, modified sequence comprising any one of SEQ ID No: 1-14. In some embodiments, the segregated, modified sequence further comprises at least one ligand attached to the 5' or 3' end of the sequence.
[0006] In another aspect, this disclosure provides an siRNA comprising an antisense strand and a sense strand, wherein the antisense strand comprises a nucleotide sequence containing any one of SEQ ID NO: 15-28, and the sense strand comprises a nucleotide sequence containing any one of SEQ ID NO: 1-14. In some embodiments, the siRNA further comprises at least one ligand attached to the 5' or 3' end of the antisense strand or the sense strand. In some embodiments, the ligand comprises at least one GalNAc moiety. In some embodiments, the ligand comprises an oleic acid moiety.
[0007] In another aspect, this disclosure provides an siRNA comprising an antisense strand comprising any one of SEQ ID NO: 15-28.
[0008] In another aspect, this disclosure provides an siRNA comprising a sense strand, said sense strand comprising any one of SEQ ID NO: 1-14.
[0009] In another aspect, this disclosure provides an siRNA comprising the sense / antisense pair detailed in Table 1A or Table A-1. In some embodiments, the siRNA further comprises at least one ligand attached to the 5' or 3' end of the antisense strand or the sense strand. In some embodiments, the ligand comprises at least one GalNAc moiety. In some embodiments, the ligand comprises an oleic acid moiety or a C16 moiety.
[0010] In another aspect, this disclosure provides an siRNA comprising an antisense strand and a sense strand, wherein the antisense strand comprises the modification pattern detailed in Table 2A or Table 2B, and the siRNA targets the C3 transcript. In some embodiments, the sense strand has the modification pattern detailed in Table 3A or Table 3B. In some embodiments, the siRNA further comprises at least one ligand attached to the 5' end of the sense strand, the 3' end of the sense strand, the 5' end of the antisense strand, the 3' end of the antisense strand, or a combination thereof. In some embodiments, the ligand comprises at least one GalNAc moiety. In some embodiments, the ligand comprises three GalNAc moieties. In some embodiments, the ligand comprises an oleic acid moiety. In some embodiments, the siRNA has the antisense strand nucleotide sequence detailed in Table 1A or Table A-1. In some embodiments, the siRNA has the sense strand nucleotide sequence detailed in Table 1A or Table A-1.
[0011] This disclosure, in another aspect, provides a method of treating a subject suffering from or at risk of complement-mediated disease, the method comprising administering to the subject a composition comprising an effective amount of siRNA as described herein. In some embodiments, after administration of the composition, the level of C3 transcripts or C3 protein in the subject or in a biological sample from the subject is reduced relative to the level before administration of the composition. In some embodiments, the level of C3 transcripts or C3 protein is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater relative to the level before administration. In some embodiments, the composition is administered to the subject intrathecally, intravenously, or subcutaneously. In some embodiments, the composition is administered to the subject's hepatocytes. In some embodiments, the composition is administered to the hepatocytes ex vivo. In some embodiments, the composition is administered to the hepatocytes in vivo.
[0012] In some embodiments, the method further includes administering a second agent to the subject. In some embodiments, the second agent is an anti-C3 antibody or a compstatin analogue. In some embodiments, the subject has a complement regulation deficiency, optionally wherein said deficiency comprises abnormally low expression of one or more complement regulatory proteins in at least some of the subject's cells. In some embodiments, the complement-mediated condition is a chronic condition.
[0013] In some embodiments, the complement-mediated condition involves complement-mediated damage to erythrocytes, optionally wherein the condition is paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome. In some embodiments, the complement-mediated condition is an autoimmune disease, optionally wherein the condition is multiple sclerosis. In some embodiments, the complement-mediated condition involves the kidneys, optionally wherein the condition is membranoproliferative glomerulonephritis, lupus nephritis, IgA nephropathy (IgAN), primary membranous nephropathy (primary MN), C3 glomerulonephropathy (C3G), or acute kidney injury. In some embodiments, the complement-mediated condition involves the central or peripheral nervous system or neuromuscular junction, optionally wherein the condition is neuromyelitis optica, Guillain-Barré syndrome, multifocal motor neuropathy, or myasthenia gravis.
[0014] In another aspect, this disclosure provides a composition comprising the siRNA described herein, as well as a carrier and / or excipient.
[0015] In another aspect, this disclosure provides a method for reducing or inhibiting complement C3 expression in cells, the method comprising contacting the cells with the siRNA described herein. In some embodiments, after the contact step, the level of C3 transcripts or C3 protein is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater relative to the level before the contact step. In some embodiments, the cells are in a subject. In some embodiments, the subject is a human. In some embodiments, the subject suffers from a complement-mediated condition.
[0016] In another aspect, this disclosure provides a method for reducing or inhibiting the expression of C3 in a subject, the method comprising contacting the subject's cells with the siRNA or composition described herein. In some embodiments, after the contact step, the level of C3 transcripts or C3 protein is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater relative to the level before the contact step. In some embodiments, the subject is a human. In some embodiments, the subject suffers from a complement-mediated condition.
[0017] In another aspect, this disclosure provides an siRNA comprising an antisense strand, wherein the antisense strand comprises any one of the siRNA antisense strand sequences detailed in Table 1B, Table A-1, or Table A-2. In another aspect, this disclosure provides an siRNA comprising a sense strand, wherein the sense strand comprises any one of the siRNA sense strand sequences detailed in Table 1B, Table A-1, or Table A-2.
[0018] In some embodiments, the siRNA described herein comprises an antisense strand and a sense strand, wherein the antisense strand and / or the sense strand comprises a nucleobase sequence according to any one of the nucleobase sequences detailed in Table A-1 or Table A-2; and wherein the sense strand comprises a modification pattern according to any one of the modification patterns detailed in Table 3A or Table 3B, and / or wherein the antisense strand comprises a modification pattern according to any one of the modification patterns detailed in Table 2A or Table 2B. Attached Figure Description
[0019] Figure 1A and 1BIn vitro dose-response activity curves of C3-targeting siRNAs. (A) A group of potent siRNAs from the HepG2 assay in Example 1A were synthesized using GalNAc conjugates, and their activity was evaluated in a free uptake study in primary human hepatocytes. (B) Primary human astrocytes were treated with TNF-α to stimulate C3 gene expression, and then siRNAs were transfected into the cells and their potency was evaluated.
[0020] Figure 2 Heatmap data of the immunostimulatory potential of siRNA from Example 1A in a human PBMC transfection assay. The ability of siRNA to stimulate the expression of IP-10 and MIP-1α in hPBMCs from three donors was evaluated. Positive and negative controls were used to validate the functionality of the assay and ensure normal responsiveness of donor cells.
[0021] Figure 3A , 3B 3C, 3D, and 3E: Samples from the experiments outlined in Example 2 were analyzed. C3 protein levels in (A) CSF and (B) plasma were assessed by immunoassay. (C) C3 gene expression levels in CNS tissues and liver were analyzed by RT-qPCR and normalized to the vector-treated animals. (D) Exposure levels of the siRNA antisense strand (AS) were quantified using LC-MS / MS. (E) CSF exposure of siRNA AS after two L-IT dose administrations.
[0022] Figure 4 Illustration of C3-targeted siRNA with a C16 ligand at the 5' end of the positive strand. The C16 ligand is linked via a C6 amine linker. Those skilled in the art will understand that other cations besides Na+ are also suitable for this type of structure. Detailed Implementation
[0023] This disclosure covers repressive RNA sequences targeting C3, such as siRNA, including compositions containing such sequences, and methods of using them.
[0024] I. Complement System To facilitate understanding of this disclosure and without any intention to limit the invention in any way, this section provides an overview of complement and its activation pathways. Further details can be found, for example, Kuby Immunology, 6th ed., 2006; Paul, WE, Fundamental Immunology, Lippincott Williams & Wilkins; 6th ed., 2008; and Walport M J., Complement. First of two parts. N Engl J Med., 344(14):1058-66,2001.
[0025] Complement is a branch of the innate immune system that plays a vital role in defending the body against infectious pathogens. The complement system comprises more than 30 serum and cellular proteins involved in three main pathways, known as the classical pathway, the alternative pathway, and the lectin pathway. The classical pathway is typically triggered by the binding of a complex of antigen and IgM or IgG antibody to C1 (although certain other activators can also initiate this pathway). Activated C1 cleaves C4 and C2 to produce C4a and C4b, as well as C2a and C2b. C4b and C2a bind to form C3 convertase, which cleaves C3 to form C3a and C3b. The binding of C3b to C3 convertase produces C5 convertase, which cleaves C5 into C5a and C5b. C3a, C4a, and C5a are anaphylatoxins and mediate various responses in acute inflammatory reactions. C3a and C5a are also chemokines that attract immune system cells, such as neutrophils. It should be understood that the original names “C2a” and “C2b” were subsequently reversed in scientific literature.
[0026] Alternative pathways are initiated and enhanced, for example, on microbial surfaces and at various complex polysaccharides. In this pathway, the hydrolysis of C3 to C3(H2O) (occurring spontaneously at low levels) leads to binding to factor B, which is cleaved by factor D to produce a liquid-phase C3 convertase. This convertase activates complement by cleaving C3 into C3a and C3b. C3b binds to a target (e.g., the cell surface) and forms a complex with factor B, which is subsequently cleaved by factor D, resulting in C3 convertase. The surface-bound C3 convertase cleaves and activates additional C3 molecules, leading to rapid C3b deposition at a site closely adjacent to the activation site, and resulting in the formation of additional C3 convertase, which in turn generates additional C3b. This process leads to a cycle of C3 cleavage and C3 convertase formation, which significantly amplifies the response. The cleavage of C3 and the binding of another C3b molecule to the C3 convertase produce a C5 convertase. The C3 and C5 convertases in this pathway are regulated by cellular molecules CR1, DAF, MCP, CD59, and fH. These proteins function through decay-accelerating activity (i.e., the ability to dissociate converting enzymes), their ability to act as cofactors in factor I degradation of C3b or C4b, or both. Typically, the presence of complement regulatory proteins on the cell surface prevents significant complement activation thereon.
[0027] In both pathways, the C5 convertase produced cleaves C5 to produce C5a and C5b. C5b then binds to C6, C7, and C8 to form C5b-8, which catalyzes the polymerization of C9 to form the C5b-9 membrane attack complex (MAC). The MAC inserts itself into the target cell membrane, leading to cell lysis. Small amounts of MAC on the cell membrane can have a variety of consequences besides cell death.
[0028] The lectin complement pathway begins with the binding of mannose-binding lectin (MBL) and MBL-associated serine protease (MASP) to carbohydrates. The MB1-1 gene (known as LMAN-1 in humans) encodes a type I integrated membrane protein located in the intermediate region between the endoplasmic reticulum and the Golgi apparatus. The MBL-2 gene encodes a soluble mannose-binding protein found in serum. In the human lectin pathway, MASP-1 and MASP-2 are involved in C4 and C2 proteolysis, leading to the aforementioned C3 convertase.
[0029] Complement activity is regulated by various mammalian proteins known as complement control proteins (CCPs) or complement activation regulators (RCA) proteins (US Patent No. 6,897,290). These proteins differ in their ligand specificity and complement inhibition mechanisms. They can accelerate the normal decay of convertases and / or act as cofactors of factor I to enzymatically cleave C3b and / or C4b into smaller fragments. CCPs are characterized by the presence of multiple (typically 4–56) homologous motifs called short common repeats (SCRs), complement control protein (CCP) modules, or SUSHI domains, approximately 50–70 amino acids in length, containing a conserved motif comprising four disulfide bonds linking cysteine (two disulfide bonds), proline, tryptophan, and numerous hydrophobic residues. The CCP family includes complement receptor type 1 (CR1; C3b:C4b receptor), complement receptor type 2 (CR2), membrane accessory factor protein (MCP; CD46), decay accelerator factor (DAF), complement factor H (fH), and C4b binding protein (C4 bp). CD59 is a membrane-bound complement regulatory protein structurally independent of CCPs. Complement regulatory proteins are generally used to limit complement activation that might otherwise occur in the cells and tissues of mammals (e.g., human hosts). Thus, “self” cells are typically protected from the detrimental effects that would otherwise occur if complement activation took place on these cells. Deficiencies or defects in complement regulatory proteins are involved in the pathogenesis of various complement-mediated disorders, such as those discussed herein.
[0030] II. Repressive RNA targeting C3 This disclosure includes compositions and methods associated with one or more nucleotide sequences that are, contain, or encode repressive RNA, which binds to messenger RNA (mRNA) produced by a target gene (e.g., C3) and inhibits its expression. The repressive RNA can be single-stranded (e.g., antisense oligonucleotide) or double-stranded nucleic acid. In some embodiments, the repressive RNA comprises a double-stranded RNA duplex, such as microRNA (miRNA) or small interfering RNA (siRNA). In some embodiments, the repressive RNA is siRNA or miRNA, or a vector containing a nucleotide sequence encoding siRNA or miRNA.
[0031] In some implementations, the repressive RNA can suppress the expression of C3 in one or more non-human species, such as non-human primates, for example, long-tailed macaques (C3). Macaca fascicularis) C3, or for example, green monkeys other than human C3. (Chlorocebus sabaeus)The rhesus macaque C3 gene has been assigned NCBI gene ID: 102131458, and the predicted amino acid and nucleotide sequences of rhesus macaque C3 are listed under NCBI RefSeq accessions XP_005587776.1 and XM_005587719.2, respectively. In some embodiments, the repressive RNA contains an antisense strand complementary to a target moiety that is identical in the human and rhesus macaque C3 transcripts. In some embodiments, the repressive RNA contains an antisense strand complementary to a target moiety in the human C3 transcript that differs from the sequence in the rhesus macaque C3 transcript by one, two, or three nucleotides. It should be understood that repressive RNA that inhibits human C3 expression can also inhibit the expression of non-primate C3 (e.g., rat or mouse C3), particularly if conserved regions of the C3 transcript are targeted.
[0032] The amino acid and nucleotide sequences of human C3 are known in the art and can be found in publicly available databases, such as the National Center for Biotechnology Information (NCBI) Reference Sequence (RefSeq) database, in which they are listed with RefSeq accession numbers NP_000055 (accession.version number NP_000055.2) and NM_000064 (accession.version number NM_000064.4), respectively (where “amino acid sequence” refers to the sequence of the C3 polypeptide, and “nucleotide sequence” in this context refers to the C3 mRNA sequence as represented in the genomic DNA; it should be understood that the actual mRNA nucleotide sequence contains U rather than T). Those skilled in the art will understand that the aforementioned sequences are for the complement C3 preprotoprotein, which includes a cleaved signal sequence and is therefore not present in the mature protein. The human C3 gene has been assigned NCBI gene ID: 718, and the genomic C3 sequence has RefSeq accession number NG_009557 (accession number.version number NG_009557.1).
[0033] In some implementations, the repressive RNA comprises a nucleic acid strand complementary to a target moiety of the C3 transcript (e.g., C3 mRNA). The target moiety can be 15-30 nucleotides long, for example, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides long, although shorter and longer target moieties are also considered.
[0034] Application of repressive RNA can reduce the levels of C3 transcripts, C3 protein, or both C3 transcripts and C3 protein in a subject or biological sample compared to levels prior to application of the composition. As used herein, biological samples can include biological fluids, cell or tissue samples, including but not limited to blood, serum or plasma samples, samples containing hepatocytes, aqueous humor, vitreous fluid, synovial fluid, cerebrospinal fluid (CSF), etc. In some embodiments, the levels of C3 transcripts or C3 protein are reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater relative to levels prior to application. C3 protein levels can be measured, for example, in a biological sample. Non-limiting examples of biological samples from which C3 can be measured include blood (serum or plasma) samples, CSF samples, aqueous humor / vitreous fluid samples, synovial fluid samples, etc.
[0035] III. siRNA In some implementations, the repressive RNA is a double-stranded RNA (dsRNA) that suppresses C3 expression via RNA interference (RNAi). RNAi is a sequence-specific posttranscriptional gene silencing process through which, for example, double-stranded RNA (dsRNA) homologous to a target locus can specifically inactivate gene function (Hammond et al., Nature Genet. 2001; 2:110-119; Sharp, Genes Dev. 1999; 13:139-141). This dsRNA-induced gene silencing can be mediated by short double-stranded small interfering RNA (siRNA) generated from longer dsRNAs via ribonuclease III cleavage (Bernstein et al., Nature, 2001; 409:363-366 and Elbashir et al., Genes Dev., 2001; 15:188-200). RNAi-mediated gene silencing is believed to occur via sequence-specific RNA degradation, where sequence specificity is determined by the interaction of the siRNA with its complementary sequence within the target RNA (see, for example, Tuschl, Chem. Biochem. 2001; 2:239-245). This disclosure includes siRNA molecules that target C3 transcripts, such as C3 mRNA.
[0036] Table 1A below details the nucleic acid sequences (e.g., nucleobase sequences) of certain siRNAs of this disclosure. The sequences in Table 1A can be used with any modification patterns detailed herein, such as those in Tables 2A, 2B, 3A, or 3B by way of non-limiting example. Tables 1B and A-2 below (in examples) also detail the nucleic acid sequences (e.g., nucleobase sequences) and modification patterns (e.g., glycoskeletal modifications, bonding modifications, 5' end modifications, etc.) of certain siRNAs of this disclosure. In some embodiments, the siRNAs of this disclosure comprise the nucleobase sequences detailed in Tables 1A, 1B, or A-2 below. In some embodiments, the siRNAs of this disclosure comprise nucleobase sequences as detailed in Tables 1A, 1B, or A-2, said nucleobase sequences having modification patterns detailed in Tables 2A or 2B (antisense strand modification patterns) or Tables 3A or 3B (sense strand modification patterns). For example, in some embodiments, the siRNA of this disclosure has a nucleobase sequence as detailed in Table 1A, an antisense strand modification pattern from Table 2A or Table 2B, and a sense strand modification pattern from Table 3A or Table 3B. In some embodiments, the siRNA of this disclosure has a nucleobase sequence as detailed in Table 1B, an antisense strand modification pattern from Table 2A or Table 2B, and a sense strand modification pattern from Table 3A or Table 3B. In some embodiments, the siRNA of this disclosure has a nucleobase sequence as detailed in Table A-2, an antisense strand modification pattern from Table 2A or Table 2B, and a sense strand modification pattern from Table 3A or Table 3B.
[0037] Regarding Table 1A, lowercase letters a, c, g, or u refer to unmodified RNA nucleotides. Regarding Table 1B, lowercase letters a, c, g, or u refer to nucleotides modified with 2'O-methyl (2'OMe). Uppercase letters followed by 'f' refer to nucleotides modified with 2'F. When 's' appears between two letters, it refers to a 3' phosphate thioester bond between the nucleotide preceding and following the 's'. When 'ps' appears at the 5' end of the sequence, the 'ps' represents a 5' phosphate thioester group on the first 5' nucleotide. The abbreviation X-GNA refers to a glycerol nucleic acid containing the nucleotide base "X"—for example, "U-GNA" refers to a glycerol nucleic acid with a uracil nucleotide base. The abbreviation "Xo" refers to an unlocked nucleic acid containing the nucleotide base "X"—for example, Uo refers to an unlocked nucleic acid with a uracil nucleotide base. The abbreviation "(vinu)" refers to a uracil nucleotide with a uracil nucleotide base, 2'OMe modification on the sugar, and a 5'... (E)Vinylphosphonate nucleotides. The abbreviation "Xm" refers to a nucleotide having an "X" nucleotide base and a sugar modified with 2'-O-methoxyethyl—for example, "Gm" refers to a nucleotide having guanine as a nucleotide base and a sugar modified with 2'-O-methoxyethyl. The abbreviation "isodX" refers to isoguanine or isocytosine nucleotides, as shown—for example, "isodG" refers to isoguanine nucleotides.
[0038] In some embodiments, the siRNA comprises a sense strand and / or an antisense strand, the sense strand and / or antisense strand containing at least 85%, at least 90%, at least 95%, or 100% identical nucleotide sequences to any of the sequences shown in Tables 1A, 1B, and A-2. In some embodiments, the siRNA comprises a sense strand, the sense strand containing the nucleotide sequence of any of the sequences shown in Tables 1A, 1B, and A-2. In some embodiments, the siRNA comprises an antisense strand, the antisense strand containing the nucleotide sequence of any of the sequences shown in Tables 1A, 1B, and A-2.
[0039] In some cases, the positive strand nucleobase sequence detailed in Tables 1A, 1B or A-2 can be modified such that the base at position 10 (counting from the 5' end) of the positive strand is mismatched, so that the base at position 10 of the positive strand does not form a classical Watson-Crick base pair with the corresponding nucleobase in the antisense strand.
[0040] In some instances, the siRNA disclosed herein comprises a suspension. Such a suspension may be complementary to or not complementary to the target sequence. For example, in some embodiments, the suspension may contain only uracil or 2'-modified uracil. In some embodiments, the suspension may be complementary to the target sequence.
[0041] Table 1A: Nucleotide Sequence Table 1B: siRNA sequences It should be noted that the siRNAs of this disclosure (including, but not limited to, the siRNAs of Tables 1A, 1B, or A-2) may contain a dangling splint, for example, a 5' and / or 3' splint, or may be blunt-ended. In this regard, the location and length of the splint (if present) can vary. The term "splint" refers to at least one unpaired nucleotide protruding from the double-stranded structure of a double-stranded nucleic acid (e.g., siRNA). For example, a 3' nucleotide splint exists when the 3' end of one strand of a double-stranded nucleic acid extends beyond the 5' end of the other complementary strand. "Blunt" or "blunt-ended" in relation to a double-stranded nucleic acid means that there is no unpaired nucleotide at that end of the double-stranded nucleic acid, i.e., no nucleotide splint. Therefore, "blunt-ended" repressive RNAs (e.g., siRNAs) are double-stranded along their entire length, i.e., without nucleotide splints at either end (although one or more unpaired nucleotides may be present within the double-stranded structure). The repressive RNAs (e.g., siRNAs) described herein include repressive RNAs with a nucleotide overhang at one end, i.e., repressive RNAs with one overhang and a blunt end, repressive RNAs with nucleotide overhangs at both ends, and blunt-ended repressive RNAs (i.e., without an overhang).
[0042] In some embodiments, the dangling splint comprises at least one, two, three, four, five, or more nucleotides. The dangling splint may comprise or consist of nucleotide or non-nucleotide portions or combinations thereof. The repressive RNA of this disclosure (e.g., siRNA) may contain one or more dangling regions, for example, at the 3' end, 5' end, or both ends of one or two strands. The dangling splint may be on the sense strand, antisense strand, or any combination thereof. In some embodiments, the nucleotides of the dangling splint may be present at the 5' end, 3' end, or both ends of the antisense strand or sense strand of the repressive RNA described herein. In some embodiments, the antisense strand of the double-stranded siRNA has a dangling splint of 1-5 nucleotides or 5-10 nucleotides, for example, a dangling splint of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides at the 3' end and / or 5' end. In some embodiments, the positive strand of the double-stranded siRNA has a 1-5 nucleotide or 5-10 nucleotide overhang, for example, a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide overhang at the 3' and / or 5' ends. In some embodiments, the length of the overhang can be 1-6 nucleotides, for example, 2-6 nucleotides, 1-5 nucleotides, 2-5 nucleotides, 1-4 nucleotides, 2-4 nucleotides, 1-3 nucleotides, 2-3 nucleotides, or 1-2 nucleotides, for example, 2 nucleotides.
[0043] A dangling strand can be the result of one strand being longer than another, or of two strands of equal length being staggered. In various embodiments, the dangling strand in the hybrid formed by the guide strand and the target RNA can be fully complementary, partially complementary, or non-complementary to the target RNA (i.e., fully complementary, partially complementary, or non-complementary to its pairing strand). For example, a 2-nucleotide dangling strand can include nucleotides complementary to positions-1 and-2 in the mRNA relative to the target site. In some embodiments, the nucleotides in the dangling region of the repressive RNA (e.g., siRNA) can each be independently modified or unmodified nucleotides, including, but not limited to: nucleotides modified with 2'-sugars, such as 2'-F, 2'-O-methyl, 2'-O-methoxyethyl-5-methyluridine (Teo), 2'-O-methoxyethyl adenosine (Aeo), 2'-O-methoxyethyl-5-methylcytidine (m5Ceo), or nucleotides not modified with 2'-sugars, such as uracil (U), thymidine (T), or deoxythymidine (dT), and any combination thereof. For example, the overhang sequence on the sense and / or antisense strands may contain UU, TT, or dTdT. In some embodiments, the overhang may comprise a ribonucleotide or a 2'-O-methyl-modified nucleotide or a combination thereof. In some embodiments, the 5' or 3' overhang of the sense, antisense, or both strands of the repressive RNA described herein may be phosphorylated. In some embodiments, the overhang region contains two nucleotides with a phosphate thioester or other non-phosphodiester bond between them, wherein the two nucleotides may be the same or different. In some embodiments, the overhang is present at the 3' end of the sense strand, the 3' end of the antisense strand, or the 3' end of both strands. In some embodiments, the 3' overhang is present in the antisense strand. In some embodiments, the 3' overhang is present in the sense strand. In some embodiments, the repressive RNA may contain a single overhang. For example, the overhang may be located at the 3' end of the sense strand, wherein the 5' end of the sense strand (together with the 3' end of the antisense strand) forms a blunt end. Alternatively, the overhang may be located at the 3' end of the antisense strand, wherein the 5' end of the antisense strand (together with the 3' end of the sense strand) forms a blunt end. In some embodiments, the 3' overhang may alternatively or additionally have a portion attached thereto, such as a ligand, a targeting portion, or a lipophilic portion.
[0044] In some embodiments, the repressive RNA of this disclosure comprises one or more native nucleobases and / or one or more modified nucleobases derived from native nucleobases. Examples include, but are not limited to, uracil, thymine, adenine, cytosine, and guanine, whose respective amino groups are protected by acyl protecting groups; 2-fluorouracil, 2-fluorocytosine, 5-bromouracil, 5-iodouracil, 2,6-diaminopurine, azacytosine, pyrimidine analogs (such as pseudoisocytosine and pseudouracil); and other modified nucleobases (such as 8-substituted purines, xanthine, or hypoxanthine, the latter two being natural degradation products). Exemplary modified nucleobases are disclosed in Chiu and Rana, RNA, 2003, 9, 1034-1048; Limbach et al., Nucleic Acids Research, 1994, 22, 2183-2196; and Revankar and Rao, Comprehensive Natural Products Chemistry, Vol. 7, 313.
[0045] Modified nucleobases also include nucleobases with expanded sizes, in which one or more aryl rings, such as phenyl rings, are added. Nucleic acid base substitutions described in the following are envisioned for use in the siRNA molecules described herein: GlenResearch catalog (www.glenresearch.com); Krueger AT et al., Acc. Chem. Res., 2007, 40, 141-150; Kool, ET, Acc. Chem. Res., 2002, 35, 936-943; Benner SA et al., Nat. Rev. Genet., 2005, 6, 553-543; Romesberg, FE et al., Curr. Opin. Chem. Biol., 2003, 7, 723-733; Hirao, I., Curr. Opin. Chem. Biol., 2006, 10, 622-627. The modified nucleobases also encompass structures that are not considered nucleobases but are other parts, such as, but not limited to, corrin or porphyrin-derived rings. Porphyrin-derived base substitutions have been described in Morales-Rojas, H and Kool, ET, Org. Lett., 2002, 4, 4377-4380.
[0046] In some embodiments, the modified nucleobases include any of the following optionally substituted structures: In some embodiments, the modified nucleobases are fluorescent. Exemplary fluorescently modified nucleobases include phenanthrene, pyrene, zirconia, isoxanthine, isoflavone, terphenyl, terthiophene, benzoterthiophene, coumarin, dioxetine, tethered zirconia, benzouracil, and naphthouracil, as shown below: In some embodiments, the modified nucleobase is unsubstituted. In some embodiments, the modified nucleobase is substituted. In some embodiments, the modified nucleobase is substituted such that it contains, for example, a heteroatom, an alkyl group, or a linker to a fluorescent moiety, a biotinylate moiety, or other protein or peptide. In some embodiments, the modified nucleobase is a "universal base" that is not a nucleobase in the most classical sense but functions similarly to a nucleobase. A representative example of such a universal base is 3-nitropyrrole.
[0047] In some embodiments, the siRNA described herein comprises a nucleoside incorporating a modified nucleotide and / or a nucleotide covalently bound to a modified sugar. Examples of nucleosides incorporating modified nucleotides include: 4-acetylcytidine; 5-(carboxyhydroxymethyl)uridine; 2'-O-methylcytidine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; dihydrouridine; 2'-O-methylpseudouridine; β,D-galactosylQ nucleoside; 2'-O-methylguanosine; N 6 -Isopentenyl adenosine; 1-methyl adenosine; 1-methyl pseudouridine; 1-methylguanosine; 1-methylinosine; 2,2-dimethylguanosine; 2-methyl adenosine; 2-methylguanosine; N 7 -Methylguanosine; 3-methylcytidine; 5-methylcytidine; 5-hydroxymethylcytidine; 5-formylcytidine; 5-carboxycytidine; N 6 -Methyladenosine; 7-methylguanosine; 5-methylaminoethyluridine; 5-methoxyaminomethyl-2-thiouridine; β,D-mannosyl-Q nucleoside; 5-methoxycarbonylmethyluridine; 5-methoxyuridine; 2-methylthio-N 6 -Isopentenyl adenosine; N-((9-β,D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine; N-((9-β,D-ribofuranosylpurine-6-yl)-N-methylcarbamoyl)threonine; uridine-5-oxyacetic acid methyl ester; uridine-5-oxyacetic acid (v); pseudouridine; Q nucleoside; 2-thiocytidine; 5-methyl-2-thiouridine; 2-thiouridine; 4-thiouridine; 5-methyluridine; 2'-O-methyl-5-methyluridine; and 2'-O-methyluridine.
[0048] In some embodiments, the nucleoside comprises a 6'-modified bicyclic nucleoside analog having (R) or (S)-chirality at the 6' position, and includes the analog described in U.S. Patent No. 7,399,845. In other embodiments, the nucleoside comprises a 5'-modified bicyclic nucleoside analog having (R) or (S)-chirality at the 5' position, and includes the analog described in U.S. Publication No. 20070287831. In some embodiments, the nucleobase or modified nucleobase is 5-bromouracil, 5-iodouracil, or 2,6-diaminopurine. In some embodiments, the nucleobase or modified nucleobase is modified by substitution with a fluorescent moiety.
[0049] Methods for preparing modified nucleobases are described in, for example, U.S. Patent Nos. 3,687,808; 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,457,191; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,4 69; 5,594,121; 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088.
[0050] In some embodiments, the siRNA described herein comprises one or more modified nucleotides, wherein a phosphate group or linker phosphorus in said nucleotide is attached to various positions of a sugar or modified sugar. As a non-limiting example, the phosphate group or linker phosphorus may be attached to the 2', 3', 4', or 5' hydroxyl portion of the sugar or modified sugar. Nucleotides incorporating the modified nucleobases described herein are also contemplated in this context.
[0051] Other modified sugars can also be incorporated into the siRNA molecule. In some embodiments, the modified sugar contains one or more substituents at the 2' position, said substituents including one of the following: -F; -CF3, -CN, -N3, -NO, -NO2, -OR', -SR', or -N(R')2, wherein each R' is independently as defined above and described herein; -O-(Cl-C 10 alkyl), -S-(C1-C 10 alkyl), -NH-(C1-C 10 Alkyl) or -N (C1-C10 alkyl)2;-O-(C2-C 10 alkenyl), -S-(C2-C) 10 alkenyl), -NH-(C2-C) 10 alkenyl) or -N(C2-C 10 alkenyl)2;-O-(C2-C 10 ynyl group), -S-(C2-C 10 ynyl group), -NH-(C2-C 10 ynyl group) or -N(C2-C 10 ynyl group)2; or -O-(C1-C 10 alkylene)-O-(C1-C 10 alkyl), -O-(C1-C 10 alkylene)-NH-(C1-C 10 Alkyl) or -O-(C1-C 10 alkylene)-NH(C1-C 10 alkyl)2、-NH-(C1-C 10 alkylene)-O-(C1-C 10 Alkyl) or -N (C1-C 10 alkyl)-(C1-C 10 alkylene)-O-(C1-C 10 Alkyl groups, wherein the alkyl, alkylene, alkenyl, and ynyl groups may be substituted or unsubstituted. Examples of substituents include, but are not limited to, -O(CH2). n OCH3 and -O(CH2) n NH2, where n is 1 to approximately 10, MOE, DMAOE, DMAEOE. Modified sugars described in this paper are also considered in: WO 2001 / 088198; and Martin et al., Helv. Chim. Acta, 1995, 78, 486-504. See also Allenson et al. (2005). J. Med. Chem 48:901-904. In some embodiments, the modified sugar comprises one or more substituents selected from: substituted silyl groups, RNA cleavage groups, reporter groups, fluorescent labels, intercalating agents, groups for improving the pharmacokinetic properties of nucleic acids, groups for improving the pharmacodynamic properties of nucleic acids, or other substituents having similar properties. In some embodiments, the modification is made at one or more of the 2', 3', 4', 5', or 6' positions of the sugar or the modified sugar, including modification at the 3' position of the sugar on the 3' terminal nucleotide or at the 5' position of the 5' terminal nucleotide.
[0052] In some embodiments, the 2'-OH of the ribose is replaced by a substituent comprising one of the following: -H, -F; -CF3, -CN, -N3, -NO, -NO2, -OR', -SR', or -N(R')2, wherein each R' is independently as defined above and described herein; -O-(Cl-C 10 alkyl), -S-(C1-C 10 alkyl), -NH-(C1-C 10 Alkyl) or -N (C1-C 10 alkyl)2;-O-(C2-C 10 alkenyl), -S-(C2-C) 10 alkenyl), -NH-(C2-C) 10 alkenyl) or -N(C2-C 10 alkenyl)2;-O-(C2-C 10 ynyl group), -S-(C2-C 10 ynyl group), -NH-(C2-C 10 ynyl group) or -N(C2-C 10 ynyl group)2; or -O-(C1-C 10 alkylene)-O-(C1-C 10 alkyl), -O-(C1-C 10 alkylene)-NH-(C1-C 10 Alkyl) or -O-(C1-C 10 alkylene)-NH(C1-C 10 alkyl)2、-NH-(C1-C 10 alkylene)-O-(C1-C 10 Alkyl) or -N (C1-C 10 alkyl)-(C1-C 10 alkylene)-O-(C1-C 10 Alkyl groups, wherein the alkyl, alkylene, alkenyl, and alkynyl groups may be substituted or unsubstituted. In some embodiments, 2'-OH is replaced by -H (deoxyribose). In some embodiments, 2'-OH is replaced by -F. In some embodiments, 2'-OH is replaced by -OR'. In some embodiments, 2'-OH is replaced by -OMe. In some embodiments, 2'-OH is replaced by -OCH2CH2OMe.
[0053] The modified sugar also includes locked nucleic acid (LNA). In some embodiments, the locked nucleic acid has the structure shown below. The locked nucleic acid indicating the following structure, wherein Ba represents a nucleobase as described herein or a modified nucleobase, and wherein R... 2s It is -OCH2C4'- The modified sugar can also encompass the unlocking nucleic acid (UNA). The UNA portion is an acyclic derivative of RNA lacking the C2'-C3' bond of the RNA ribose ring.
[0054] In some embodiments, the modified sugar is an ENA, such as those described in Seth et al., J Am Chem Soc. 2010 Oct. 27; 132(42): 14942-14950. In some embodiments, the modified sugar is any sugar present in XNA (heteronucleotides), such as arabinose, anhydrous hexitol, threonose, 2'-fluoroarabinose, or cyclohexene.
[0055] Modified sugars include sugar analogs, such as cyclobutyl or cyclopentyl moieties replacing the pentofuranosyl sugar (see, for example, U.S. Patent Nos. 4,981,957; 5,118,800; 5,319,080; and 5,359,044). Some considered modified sugars include sugars in which the oxygen atom in the ribose ring is replaced by nitrogen, sulfur, selenium, or carbon. In some embodiments, the modified sugar is a modified ribose in which the oxygen atom in the ribose ring is replaced by nitrogen, and wherein said nitrogen is optionally replaced by an alkyl group (e.g., methyl, ethyl, isopropyl, etc.).
[0056] Non-limiting examples of modified sugars include glycerol, which forms glycerol nucleic acid (GNA) analogs. One example of a GNA analog is described in: Zhang, R et al., J. Am. Chem. Soc., 2008, 130, 5846-5847; Zhang, L et al., J. Am. Chem. Soc., 2005, 127, 4174-4175; and Tsai, CH et al., PNAS, 2007, 14598-14603. Another example of a GNA-derived analog, namely a flexible nucleic acid (FNA) based on a mixture of formylglycerol and acetals, is described in Joyce, GF et al., PNAS, 1987, 84, 4398-4402; and Heuberger, BD and Switcher, C., J. Am. Chem. Soc., 2008, 130, 412-413. Other non-limiting examples of modified sugars include hexopyranosyl (6' to 4'), pentopyranosyl (4' to 2'), pentopyranosyl (4' to 3'), or tetrafuranosyl (3' to 2') sugars.
[0057] Modified sugars and sugar mimics can be prepared by methods known in the art, including but not limited to: A. Eschenmoser, Science (1999), 284:2118; M. Bohringer et al., Helv. Chim. Acta (1992), 75:1416-1477; M. Egli et al., J. Am. Chem. Soc. (2006), 128(33):10847-56; A. Eschenmoser in Chemical Synthesis: Gnosis to Prognosis, C. Chatgilialoglu and V. Sniekus, Ed., (Kluwer Academic, Netherlands, 1996), p.293; K.-U. Schoning et al., Science (2000), 290:1347-1351; A. Eschenmoser et al., Helv. Chim. Acta (1992), 75:218; J. Hunziker et al., Helv. Chim. Acta (1993), 76:259; G. Otting et al., Helv. Chim. Acta (1993), 76:2701; K. Groebke et al., Helv. Chim. Acta (1998), 81:375; and A. Eschenmoser, Science (1999), 284:2118. Modifications to the 2' modification can be found in Verma, S. et al., Annu. Rev. Biochem., 1998, 67, 99-134 and all references therein. For specific modifications to ribose, see the following references: 2'-fluorination (Kawasaki et al., J. Med. Chem., 1993, 36, 831-841), 2'-MOE (Martin, P. Helv. Chim. Acta 1996, 79, 1930-1938), "LNA" (Wengel, J. Acc. Chem. Res. 1999, 32, 301-310); PCT Publication No. WO2012 / 030683.
[0058] In some embodiments, the siRNA disclosed herein may cover one or more glycerol nucleic acid (GNA) bases, one or more UNA (unlocking nucleic acid) bases, or combinations thereof. For example, in some embodiments, the siRNA disclosed herein may contain a GNA or UNA base at the seventh position of the antisense strand, wherein the numbering begins at the 5' position.
[0059] According to certain embodiments, various nucleotide modifications or nucleotide modification patterns may be selectively used in the sense or antisense strand of the repressive RNA (e.g., siRNA) described herein. For example, in some embodiments, unmodified ribonucleotides may be used in the antisense strand (at least within its duplex portion), while modified nucleotides and / or modified or unmodified deoxyribonucleotides are employed at some or all positions on the sense strand. In some embodiments, a specific modification pattern is employed in part or all of one or both strands of the siRNA. Nucleotide modifications may occur in any of a variety of patterns. For example, alternating patterns may be used. For example, the antisense strand, sense strand, or both may have a 2'-O-methyl or 2'-fluorine modification at every other nucleotide. In some embodiments, the repressive RNA (e.g., siRNA) comprises a sense strand and / or an antisense strand having at least one unmodified nucleotide.
[0060] In some implementations, each nucleotide in the sense and antisense strands of the repressive RNA (e.g., siRNA) can be modified. Each nucleotide can be modified with the same or different modifications, which, by way of non-limiting examples, can include: changes to one or more of the unlinked and / or linked phosphate groups; changes to the composition of the ribose, such as changes to the 2' hydroxyl group on the ribose; a complete replacement of the phosphate moiety with a "dephosphorylation" linker; modifications or replacements of naturally occurring bases; and replacements or modifications to the ribose-phosphate backbone.
[0061] In some embodiments, one or more residues of the sense and antisense strands are independently modified with LNA, CRN, cET, UNA, GNA, HNA (1,5-dehydrated hexadiol nucleic acid), CeNA (cyclohexene nucleic acid—a DNA mimic in which the deoxyribose is replaced by a six-membered cyclohexene ring), 2'-methoxyethyl, 2'-O-methyl, 2'-O-allyl, 2'-C-allyl, 2'-deoxy, 2'-hydroxy, or 2'-fluorine. The strands may contain more than one modification. In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more, such as 100%, of the residues of the sense and antisense strands are independently modified with 2'-O-methyl or 2'-fluorine. In some embodiments, at least two different modifications are present on the sense and antisense strands. These two modifications may be 2'-O-methyl or 2'-fluorine modifications, or other modifications.
[0062] In some embodiments, the siRNA of this disclosure comprises a sense strand and an antisense strand, wherein the sense strand has a modification pattern according to any of the modification patterns detailed in Tables 3A or 3B below, and the antisense strand has a modification pattern according to any of the modification patterns detailed in Tables 2A or 2B below. That is, each of the sense strand modification patterns detailed in Tables 3A or 3B can be paired with any of the antisense strand modification patterns detailed in Tables 2A or 2B. Any of these combinations of sense / antisense strand modification patterns can be used to create a C3-targeting siRNA duplex. Specifically, any of these combinations of sense / antisense strand modification patterns can be used in conjunction with any of the nucleotide sequences detailed in Tables 1A, 1B, or A-2.
[0063] In some embodiments, the repressive RNA (e.g., siRNA) of this disclosure comprises an antisense strand having a modification pattern according to any of the modification patterns described in Tables 2A or 2B. In some embodiments, the siRNA of this disclosure may comprise a sense strand nucleobase sequence and an antisense strand, wherein the sense strand nucleobase sequence is according to any of the sense strands detailed in Tables 1A, 1B, or A-2, and the antisense strand comprises a modification pattern according to any of the modification patterns detailed in Tables 2A or 2B. In specific embodiments, the siRNA of this disclosure may comprise a sense strand nucleobase sequence and an antisense strand nucleobase sequence, wherein the sense strand nucleobase sequence is any one of the sense strands detailed in Tables 1A, 1B, or A-2, and the antisense strand nucleobase sequence is any one of the antisense strand nucleobase sequences detailed in Tables 1A, 1B, or A-2, and the antisense strand nucleobase sequence has an antisense modification pattern according to any one of the modification patterns detailed in Tables 2A or 2B. In some embodiments, the siRNA of this disclosure may comprise an antisense strand nucleobase sequence and a sense strand modification pattern, wherein the antisense strand nucleobase sequence is any one of the antisense strands detailed in Tables 1A, 1B, or A-2, and the sense strand modification pattern is any one of the modification patterns detailed in Tables 3A or 3B. In a specific implementation, the siRNA of this disclosure may comprise an antisense strand nucleobase sequence and a sense strand nucleobase sequence, wherein the antisense strand nucleobase sequence is any one of the antisense strands detailed in Table 1A, Table 1B, or Table A-2, the sense strand nucleobase sequence is any one of the sense strand nucleobase sequences detailed in Table 1A, Table 1B, or Table A-2, and the sense strand nucleobase sequence has a sense strand modification pattern according to any one of the modification patterns detailed in Table 3A or 3B.
[0064] In some embodiments, the siRNA disclosed herein comprises double strands 1B, 7B, 15B, 21B, 30B, 41B, 52B, 84B, 85B, 86B, 87B, 101B, 103B, 106B, 121B, 129B, 130B, 161B, 163B, 166B, 170B, 219B, 220B, 222B, 225B, 226B, 227B, 228B, 232B, 238B, or 243B as detailed in Table A-2. In some embodiments, the siRNA of this disclosure comprises double strands 1B, 7B, 15B, 21B, 30B, 41B, 52B, 84B, 85B, 86B, 87B, 101B, 103B, 106B, 121B, 161B, 163B, 166B, 170B, 219B, 220B, 225B, 227B, 228B, or 243B as detailed in Table A-2. In some embodiments, the siRNA of this disclosure comprises double strands 129B, 130B, 222B, 226B, 232B, or 238B as detailed in Table A-2. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 29. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 30. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 31. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 32. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, or 83. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 72. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 73. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 74. In some embodiments, the siRNA of this disclosure comprises SEQ ID NO: 75. For each of these embodiments, the siRNA may comprise a ligand conjugated to a terminal (e.g., the 3' or 5' end of the sense or antisense strand). In some embodiments, the ligand may be a GalNAc ligand, an oleic acid moiety, or a C16 moiety. For example, the siRNA detailed herein can be conjugated to a GalNAc ligand, an oleic acid moiety, or a C16 moiety at the 5' end of the sense strand, the 3' end of the sense strand, the 5' end of the antisense strand, or the 3' end of the antisense strand. Methods of ligand conjugation to siRNA are known in the art and may include a C6 amine linker.
[0065] In some implementations, the siRNA detailed herein can be conjugated at the 5' end of the positive strand, as shown in formula (I): (ligand) - (connector) - 5' end of the justice chain.
[0066] In some embodiments of formula (I), the (ligand) is a GalNAc ligand, an oleic acid moiety, or a C16 moiety, and the (connector) is any suitable connector known in the art. In some embodiments of formula (I), the (ligand) is a GalNAc ligand, an oleic acid moiety, or a C16 moiety, and the (connector) is a C6 amine connector. For example, the following structure illustrates one embodiment of a C16 moiety connected to the 5' end of a nucleobase via a C6 amine connector: .
[0067] In some embodiments of Formula (I), the (ligand) is an oleic acid moiety or a C16 moiety, and the (connector) is a C6 amine connector. In some embodiments of Formula (I), the (ligand) is a C18:1 moiety, a C16:0 moiety, or a C16:1 moiety, and the (connector) is a C6 amine connector. In some embodiments of Formula (I), the (ligand) is a C18:1 moiety, and the (connector) is a C6 amine connector. In some embodiments of Formula (I), the (ligand) is a C16:0 moiety, and the (connector) is a C6 amine connector. In some embodiments of Formula (I), the (ligand) is a C16:1 moiety, and the (connector) is a C6 amine connector.
[0068] In some embodiments of formula (I), the (connector) is a C6 amine connector, and the (ligand) is a suitable ligand known in the art. For example, formula (I) can be (ligand)-NH-(CH2)6- (the 5' end of the positive chain). In some embodiments of formula (I), the (ligand)-(connector) is CH3(CH2). 14 -CO-NH-(CH2)6- (5' end of the positive chain). In some embodiments of formula (I), the (ligand)-(connector) is CH3(CH2). 16 -CO-NH-(CH2)6- (5' end of the positive chain). In some embodiments of formula (I), the (ligand)-(connector) is CH3(CH2)5-CHCH-(CH2)7-CO-NH-(CH2)6- (5' end of the positive chain). In some embodiments of formula (I), the (ligand)-(connector) is CH3(CH2)5-CHCH-(CH2)7-CO-NH-(CH2)6- (5' end of the positive chain).
[0069] In some embodiments, the siRNA detailed herein may be conjugated to the C16:0 portion at the 5' end of the positive strand via a C6 amine linker. In other embodiments, the siRNA detailed herein may be conjugated to the C16:1 portion at the 5' end of the positive strand via a C6 amine linker. In still other embodiments, the siRNA detailed herein may be conjugated to the C18:1 portion at the 5' end of the positive strand via a C6 amine linker.
[0070] Regarding Tables 2A, 2B, 3A, and 3B, "OMe" refers to a nucleotide modified with 2'O-methyl. 'F' refers to a nucleotide modified with 2'F. When 's' appears between two positions, it refers to a 3' phosphate thioester between the nucleotide preceding and following the 's'. When 'ps' appears at the 5' end of the sequence, the 'ps' represents a 5' phosphate thioester group on the first 5' nucleotide. The abbreviation GNA refers to glycerol nucleic acid. The abbreviation "U" or "UNA" refers to unlocked nucleic acid. The abbreviation "5VP" refers to 5'( E Vinylphosphonate. The abbreviation "MOE" refers to a nucleotide with a sugar modified by 2'-O-methoxyethyl. The abbreviation "isod" refers to isoguanosine or isocytosine nucleobases. The symbol "-" indicates an unmodified RNA base. The abbreviation "OB" refers to a nucleotide with a sugar modified by 2'-O-benzyl. In some embodiments, the siRNA of this disclosure (e.g., the siRNAs detailed in Tables 1A, 1B, or A-2) may comprise a ligand (e.g., a GalNAc ligand, such as GalNAc of formula XD or XE described herein, an oleic acid moiety, a C16 moiety, a LAT1 binding moiety, etc.) conjugated to a terminal (e.g., the 3' or 5' end of the sense or antisense strand). Methods of ligand conjugation to siRNA are known in the art and may include a C6 amine linker. In some embodiments, the ligands used herein are designed to cross the blood-brain barrier.
[0071] Repressive RNA (e.g., siRNA) may further comprise at least one phosphate-thioester and / or methylphosphonate nucleotide linker. In some embodiments, the nucleotide linker modification may occur on each nucleotide of the sense strand and / or antisense strand; each nucleotide linker modification may occur in an alternating pattern on the sense strand and / or antisense strand; or the sense strand or antisense strand may contain two nucleotide linker modifications, both in an alternating pattern. The alternating pattern of the nucleotide linker modification on the sense strand may be the same as or different from that on the antisense strand, and the alternating pattern of the nucleotide linker modification on the sense strand may be offset relative to the alternating pattern of the nucleotide linker modification on the antisense strand. In some embodiments, the repressive RNA (e.g., siRNA) comprises 6-8 phosphate-thioester nucleotide links. In some embodiments, the antisense strand comprises two phosphate-thioester nucleotide links at the 5' end and two phosphate-thioester nucleotide links at the 3' end, and the sense strand comprises at least two phosphate-thioester nucleotide links at either the 5' end or the 3' end. In certain embodiments, the modification patterns detailed in Tables 2A, 2B, 3A, or 3B may contain more or fewer thiophosphate links than depicted in those tables. For example, the modification patterns depicted in Tables 2A, 2B, 3A, or 3B may contain at least one, two, three, four, five, six, seven, eight, or more than eight thiophosphate links. In each of these embodiments, the thiophosphate links may have a specific chiral orientation, such as Rp or Sp.
[0072] In some embodiments, the ligand is one or more GalNAc derivatives, which are attached via a divalent or trivalent linker. In some embodiments, the ligand is depicted in formula XA, XB, or XC, or another GalNAc structure as shown below. In some embodiments, the oleic acid moiety or C16 moiety can be attached to the siRNA described herein via a C6-amine linker.
[0073] In some embodiments, the ligand attaches to the 3' end of the positive chain. In some embodiments, the attachment is depicted in Formula XD below.
[0074] In some implementations, the repressive RNA (e.g., siRNA) also contains at least one phosphate thioester or methylphosphonate nucleotide linker.
[0075] In some embodiments, the ligand targets nucleic acid molecules to hepatocytes. For example, in some embodiments, the ligand binds to a hepatocyte-specific asialic acid glycoprotein receptor (ASGPR), and the ligand comprises, for example, a galactose derivative, such as GalNAc.
[0076] In some embodiments, the repressive RNA (e.g., siRNA) is conjugated to or otherwise physically associated with one or more portions that modulate, for example, enhance, the activity, stability, cellular distribution and / or cellular uptake of the repressive RNA (e.g., siRNA), and / or alter one or more physical properties of the repressive RNA (e.g., siRNA), such as charge or solubility. In some embodiments, the portion may comprise an antibody or ligand. The ligand may be an aptamer, carbohydrate, lectin, protein, peptide, glycoprotein, lipid, cholesterol, steroid, bile acid, nucleic acid hormone, growth factor, or receptor. In some embodiments, a biologically inactive variant of a naturally occurring hormone, growth factor, or other ligand may be used. In some embodiments, the portion comprises a targeting portion that targets the repressive RNA (e.g., siRNA) to a specific cell type, such as hepatocytes, nerve cells, or ophthalmic cell types. In some embodiments, the targeting portion binds to the hepatocyte-specific desialylate glycoprotein receptor (ASGPR). In some implementations, the targeting portion binds to receptor-mediated transcytosis targets, such as transferrin receptor 1 (TrF1), large neutral amino acid transporter 1 (LAT1), or differentiation cluster 98 (CD98).
[0077] In some implementations, the portion is attached to repressive RNA (e.g., siRNA) via a reversible linker. A “reversible linker” is a linker containing a reversible bond. A “reversible bond” (also called an unstable bond or a cleavable bond) is a covalent bond other than a covalent bond with a hydrogen atom that can be selectively broken or cleaved under selected conditions, at a rate faster than other bonds in the molecule that can be selectively broken or cleaved without substantially breaking or cleaving other covalent bonds in the same molecule. The cleavage or instability of a bond can be expressed as the half-life of the bond cleavage (tc). 1 / 2The term is used to describe the reversible bond as (the time required for half of the bond to cleave). Unless otherwise stated, the reversible bond referred to herein is a "physiologically reversible bond," meaning that the bond is cleavable under conditions commonly encountered or similar to those encountered in mammalian bodies. A physiologically reversible link is a link containing at least one physiologically reversible bond. In some embodiments, the physiologically reversible bond is reversible under mammalian cellular conditions, including chemical conditions such as pH, temperature, oxidative or reducing conditions or reagents, and salt concentrations found or similar to those found in mammalian cells. Mammalian cellular conditions also include enzymatic activities commonly present in mammalian cells, such as enzymatic activities from proteolytic enzymes or hydrolases. Enzyme-unstable bonds are cleaved by enzymes in vivo, such as intracellular enzymes. pH-unstable bonds are cleaved at pH values less than or equal to 7.0. Examples of reversible bonds and links, and their use for conjugating portions of repressive RNA (e.g., siRNA), are described, for example, in U.S. Patent Application Publications 20130281685 and 20150273081.
[0078] In some embodiments, a portion comprises a protein transduction domain (PTD). A protein transduction domain is a polypeptide or a portion thereof that facilitates the uptake of a foreign molecule attached to the domain (such foreign molecule may be referred to as "cargo"). A protein transduction domain that may be a peptide may be referred to as a cell-penetrating peptide (CPP). Various protein transduction domains / peptides are known in the art. PTDs include a variety of naturally occurring or synthetic arginine-rich peptides. Arginine-rich peptides are peptides containing at least 30% arginine residues, such as at least 40%, 50%, 60%, or more. Examples of PTDs include TAT (at least amino acids 49-56), the Antenopedia homology domain, HSV VP22, RVG, angopep, and polyarginine. Such peptides may be cationic, hydrophobic, or amphiphilic peptides and may include non-standard amino acids and / or various modifications or variants, such as using cyclic, reverse, inverted, reverse-inverted, or peptide-like versions. The attachment of the PTD to the cargo may be covalent or non-covalent.
[0079] Exemplary PTDs that can be used are described in U.S. Patent Application Publications Nos. 20090093026, 20090093425, 20120142763, 20150238516, and 20160215022. A PTD may comprise two or more PTDs (e.g., 2 to 10 PTDs), which may be identical or different. PTDs may be directly connected to each other or may be separated by connecting portions, which may contain one or more amino acid portions and / or one or more non-amino acid portions, such as alkyl chains or oligomeric glycol portions.
[0080] In some embodiments, the repressive RNA (e.g., siRNA) comprises or is physically associated with an anion-charge-neutralizing portion. An anion-charge-neutralizing portion refers to a molecule or chemical group capable of reducing the total net anion charge of the nucleic acid with which it is physically associated. One or more anion-charge-neutralizing molecules or groups may associate with the nucleic acid, each independently contributing to a reduction in anion charge and / or an increase in cationic charge. By charge neutralization means that the anion charge of the nucleic acid is reduced, neutralized, or made more cationic relative to the same nucleic acid in the absence of anion-charge-neutralizing molecules or groups. Phosphodiester and / or thiophosphate protecting groups are examples of anion-charge-neutralizing groups. In some embodiments, the repressive RNA (e.g., siRNA) comprises a protecting group at one or more sites that reduces the net anion charge of a backbone containing negatively charged groups (e.g., a phosphodiester or thiophosphate backbone). In some embodiments, the negatively charged phosphodiester backbone is neutralized by synthesizing a biologically reversible phosphotriester protecting group, which is converted intracellularly into a charged phosphodiester bond by the action of a cytoplasmic thioesterase, thereby producing an agent biologically active for inhibiting expression, such as repressive RNA that can mediate RNAi (e.g., siRNA). Such agents (sometimes referred to as short interfering RNA neutral bodies (siRNNs)) can therefore be used as siRNA prodrugs. It should be understood that the backbone does not need to be completely neutralized (i.e., uncharged). In some embodiments, 5% to 100% of the phosphate groups are protected, for example, 25%-50%, 50% to 75%, or 75% to 100%. In some embodiments, at least 5, 6, 7, 8, 9, or 10 phosphate groups on one or both strands are protected. Useful phosphodiester and / or thiophosphate protecting groups, their preparation methods, and examples of their use in nucleic acids (e.g., for generating prodrugs for RNAi agents) are described in the prior art, for example, in U.S. Patent Application Publications 20110294869, 20090093425, 20120142763, and 20150238516. In certain embodiments, siRNAs disclosed in Tables 1A, 1B, or A-2, or siRNAs containing the modification patterns disclosed in Tables 2A, 2B, 3A, or 3B, may contain the protecting groups detailed above. In various embodiments, siRNAs may contain any of the modifications described herein. For example, in some embodiments, the modification pattern may contain a 2' sugar modification (e.g., 2'-F, 2'-O-Me). Furthermore, siRNAs may have any of the conformations or modification patterns described herein.
[0081] In some embodiments, the portion attached to the repressive RNA (e.g., siRNA) comprises a carbohydrate. Representative carbohydrates include monosaccharides, disaccharides, trisaccharides, and oligosaccharides containing about 4, 5, 6, 7, 8, or 9 monosaccharide units. In some embodiments, the carbohydrate comprises galactose or a galactose derivative, such as galactosamine, N-formylgalactosamine, N-acetylgalactosamine, N-propionylgalactosamine, N-butyrylgalactosamine, and N-iso-butyrylgalactosamine. In some embodiments of particular interest, the galactose derivative comprises N-acetylgalactosamine (GalNAc). In some embodiments, the portion comprises multiple instances of galactose or galactose derivatives, such as multiple N-acetylgalactosamine moieties, for example, 3 GalNAc moieties. As used herein, the term "galactose derivative" includes galactose and derivatives of galactose that have an affinity for the desialylate glycoprotein receptor equal to or greater than that of galactose. The term "galactose cluster" refers to a structure comprising at least two galactose derivatives physically associated with each other, typically covalently attached to another portion. In some embodiments, the galactose cluster has 2-10 (e.g., 6) or 2-4 (e.g., 3) terminal galactose derivatives. The terminal galactose derivatives can be attached to another portion via their C-1 carbon. In some embodiments, two or more, such as three, galactose derivatives are attached to a portion serving as a branch point, and said portion can be attached to a repressive RNA (e.g., siRNA). In some embodiments, the galactose derivatives are attached to the branch point portion via a linker or spacer. In some embodiments, the branch point portion can be attached to a repressive RNA (e.g., siRNA) via a linker or spacer. For example, in some embodiments, the galactose derivatives are attached to the branch point via a linker or spacer comprising an amide, carbonyl, alkyl, oligoethylene glycol moiety, or a combination thereof. In some embodiments, the linker or spacer attached to each galactose derivative is identical. In some embodiments, the galactose cluster has three terminal galactosamines or galactosamine derivatives (e.g., GalNAc), each terminal galactosamine or galactosamine derivative having affinity for the desialyl glycoprotein receptor. A structure in which the three terminal GalNAc moieties (e.g., via the C-1 carbon of the sugar) are attached to a portion serving as a branch point may be referred to as triantennae N-acetylgalactosamine (GalNAc3). In some embodiments, one or more monomeric units containing galactose derivatives can be site-specifically incorporated into repressive RNA (e.g., siRNA). Such monomeric units containing galactose derivatives may comprise galactose derivatives, such as GalNAc, attached to nucleoside or non-nucleoside moieties.In some embodiments, at least three nucleoside-GalNAc monomers or at least three non-nucleoside-GalNAc monomers are site-specifically incorporated into repressive RNA (e.g., siRNA). In some embodiments, such incorporation can occur during solid-phase synthesis using phosphoramidite chemistry or via synthetic post-conjugation. In some embodiments, galactose derivative-containing monomer units are linked to each other via phosphodiester bonds and / or to nucleosides that do not have the attached galactose derivative-containing repressive RNA (e.g., siRNA). In some embodiments, two, three, or more galactose derivative-containing monomer units are arranged sequentially, i.e., without any insert units lacking the galactose derivative. In some embodiments, a carbohydrate, such as a galactose cluster, such as triantennae N-acetylgalactosamine, or two or more GalNAc-containing monomer units are present at the ends of the strand, such as at the 3' end of the sense strand or the 5' end of the antisense strand. Exemplary carbohydrates (e.g., galactose clusters), galactose-derived monomeric units, carbohydrate-modified repressive RNAs, and methods of their preparation and use are described in the following: U.S. Patent Application Publications Nos. 20090203135, 20090239814, 20110207799, 20120157509, 20150247143, US Pub.'124; Nair, JK, et al., J. Am. Chem. Soc. 136, 16958-16961 (2014); Matsuda, S., et al., ACS Chem. Biol. 10, 1181-1187 (2015); Rajeev, K., et al., ChemBioChem 16, 903-908 (2015); Migawa, M T., et al., BioorgMed Chem Lett. 26(9):2194-7 (2016); Prakash, TP, et al., J Med Chem. 59(6):2718-33 (2016). Exemplary galactose clusters are described below. The other GalNAc structure is described below (and can be synthesized as described in Sharma et al., Bioconjug. Chem. 29:2478-2488 (2018)): In some implementations, m=0 and n=2. In some implementations, m=1 and n=1. In some implementations, m=1 and n=2. In some implementations, m=1 and n=3. Those skilled in the art will understand that the structure of the connection portion that links each GalNAc to the branch point can vary. In some embodiments, a repressive RNA (e.g., siRNA) is conjugated to the GalNAc described below: (The GalNAc mentioned therein can be attached to either the 3' or 5' end of any chain (e.g., the justice chain). In some embodiments, the repressive RNA of this disclosure (e.g., siRNA) is conjugated to a GalNAc ligand (e.g., GalNAc of formula XD or XE). For example, the siRNAs of Table 1A, Table 1B, or Table A-2 are conjugated to GalNAc ligands (e.g., GalNAc of formula XD or XE).
[0082] In some embodiments, a GalNAc ligand (e.g., as shown in Formula XD or XE) is conjugated to the 3'-terminal nucleotide of the sense or antisense strand of the siRNA. In some embodiments, the GalNAc ligand (e.g., as shown in Formula XD or XE) is conjugated to the 3' position of the sugar on the 3'-terminal nucleotide of the sense or antisense strand of the siRNA. In each of these embodiments, the siRNA may be one of the siRNAs detailed in Tables 1A, 1B, or A-2.
[0083] In some embodiments, a GalNAc ligand (e.g., as shown in Formula XD or XE) is conjugated to the 5'-terminal nucleotide of the sense or antisense strand of the siRNA. In some embodiments, the GalNAc ligand (e.g., as shown in Formula XD or XE) is conjugated to the 5' position of the 5'-terminal nucleotide of the sense or antisense strand of the siRNA. In each of these embodiments, the siRNA may be one of the siRNAs detailed in Tables 1A, 1B, or A-2.
[0084] In some implementations, when the repressive RNA is conjugated to a ligand (e.g., GalNAc ligand), the repressive RNA may not include modifications to the nucleotides conjugated to the ligand (e.g., phosphate thioester bonds "PS").
[0085] In some embodiments, the siRNA is conjugated to a GalNAc ligand at one end of either the sense or antisense strand (e.g., as shown in Formula XD or XE). In some embodiments, the other three ends not conjugated to the GalNAc ligand contain modifications, such as phosphate thioester bonds (“PS”). In some embodiments, the modification includes PS bonds between two, three, or four 5' or 3' terminal nucleotides. In some embodiments, the ends conjugated to the GalNAc ligand do not contain phosphate thioester bonds between two, three, or four 5' or 3' terminal nucleotides.
[0086] In some implementations, the siRNA described herein can be conjugated to a galactose structure as shown below: In some embodiments, the connector comprises an amide, carbonyl, alkyl, oligomeric glycol moiety, or a combination thereof.
[0087] In some implementations, the siRNA described herein can be conjugated to a galactose structure as shown below: In some embodiments, the connector comprises an amide, carbonyl, alkyl, oligomeric glycol moiety, or a combination thereof.
[0088] Methods for synthesizing GalNAc ligands, methods for conjugating GalNAc ligands to repressive RNAs, and other GalNAc ligands are known in the art, including, for example, those described in WO 2017 / 021385, WO 2017 / 178656, WO 2018 / 215391, WO 2019 / 145543, WO 2017 / 084987, WO 2017 / 055423, and WO 2012 / 083046, which are incorporated herein by reference in their entirety.
[0089] In some implementations, the repressive RNA (e.g., siRNA) is conjugated to a ligand as described below: Where X is O or S. In most embodiments, X is O. Those skilled in the art will understand that the structure of the linking portion connecting the galactose cluster and the phosphate group can vary.
[0090] In some embodiments, the portion comprises a lipophilic moiety. In some embodiments, the lipophilic moiety comprises tocopherol, such as α-tocopherol. In some embodiments, the lipophilic moiety comprises cholesterol. In some embodiments, the lipophilic compound comprises an alkyl group or a heteroalkyl group. In some embodiments, the lipophilic compound comprises palmitoyl, hexadec-8-enoyl, oleoyl, (9E,12E)-octadec-9,12-dienoyl, dioctanoyl, or C16-C20 acyl. In some embodiments, the lipophilic moiety comprises at least 16 carbon atoms. In some embodiments, the lipophilic moiety comprises -(CH). n -NH-(C═O)-(CH) m -CH3. In some embodiments, n and m are each independently between 1 and 20. In some embodiments, n+m is at least 10, 12, 14, or 16. In some embodiments, the lipophilic portion is shown below and / or attached to the sugar portion shown below. Typically, the portion may be attached to the terminal or internal subunit of a repressive RNA (e.g., siRNA). In some embodiments, the portion is attached to a modified subunit of a repressive RNA (e.g., siRNA). Suitable methods for manufacturing nucleic acids having portions conjugated thereto are known to those skilled in the art. A nucleic acid chain comprising a modified nucleotide containing a reactive functional group, the nucleic acid chain being reactable with a portion containing a second reactive functional group, wherein the first reactive functional group and the second reactive functional group are capable of reacting with each other under conditions compatible with maintaining the structure of the nucleic acid chain. In some embodiments, the portion may be attached to a sense strand or antisense strand before the sense strand or antisense strand hybridizes with a complementary antisense strand or sense strand, respectively. In some embodiments, the chain may be hybridized to form a duplex before the portion is introduced. Generally, various conjugation methods described in this disclosure can be used. See, for example, Hermanson, G., Bioconjugate Techniques, 2nd edition, Academic Press, San Diego, 2008.
[0091] In some embodiments, the repressive RNA (e.g., siRNA) is a chimeric siRNA. As used herein, a "chimeric" siRNA is an siRNA containing two or more chemically distinct regions, each region comprising at least one monomeric unit, wherein said regions impart different properties to the compound. In some embodiments, at least one region is modified to impart increased resistance to nuclease degradation, increased cellular uptake, and / or increased binding affinity to target nucleic acids to the siRNA, and at least one additional region of the siRNA can serve as a substrate for an enzyme (e.g., RNase H) capable of cleaving RNA:DNA or RNA:RNA hybrids. In some embodiments, at least one region of the siRNA can serve as a substrate for an enzyme (e.g., RNase H) capable of cleaving RNA:DNA or RNA:RNA hybrids, and at least one region can inhibit translation through steric hindrance.
[0092] In some embodiments, the repressive RNA (e.g., siRNA) described herein can be introduced into target cells as an annealed double-stranded siRNA. In some embodiments, the repressive RNA (e.g., siRNA) described herein is introduced into target cells as a single-stranded sense nucleic acid sequence and an antisense nucleic acid sequence, which, once inside the target cell, anneal to form a repressive RNA (e.g., siRNA) double strand.
[0093] The repressive RNA described herein can be synthesized using standard methods known in the art, such as automated synthesizers, liquid-phase synthesis, and stirred-bed synthesis. RNA produced by such methods tends to be highly purified and efficiently annealed to form double strands of repressive RNA (e.g., siRNA). Following chemical synthesis, single-stranded RNA molecules can be deprotected, annealed to form siRNA, and purified (e.g., by gel electrophoresis or HPLC). Alternatively, standard procedures can be used for the in vitro transcription of RNA from a DNA template, for example, carrying one or more RNA polymerase promoter sequences (e.g., T7 or SP6 RNA polymerase promoter sequences). Protocols for preparing siRNA using T7 RNA polymerase are known in the art (see, for example, Donze and Picard, Nucleic Acids Res. 2002; 30:e46; and Yu et al., Proc. Natl. Acad. Sci. USA 2002; 99:6047-6052). The sense and antisense transcripts can be synthesized in two independent reactions followed by annealing, or they can be synthesized simultaneously in a single reaction.
[0094] IV. Composition and Application Repressive RNAs (such as siRNAs described herein) or vectors containing nucleotide sequences encoding siRNAs or miRNAs described herein can be used to treat complement-mediated diseases or conditions, such as in subjects who have or are susceptible to complement-mediated diseases or conditions described herein. The route and / or manner of administration of the repressive RNAs described herein can vary depending on the desired outcome. Those skilled in the art (i.e., physicians) will recognize that dosing regimens can be tailored to provide a desired response, such as a therapeutic response. Methods of administration include, but are not limited to: intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intrathecal (e.g., intracisional or via lumbar puncture), intravenous, intravaginal, intravitreal, suprachoroidal, subretinal, percutaneous, rectal, inhalation, or local administration, particularly to the ear, nose, eye, or skin. In some embodiments, the composition of the repressive RNA is delivered to the central nervous system (CNS). The method of administration is determined by the practitioner.
[0095] Those skilled in the art will understand that repressive RNAs (such as siRNAs or miRNAs described herein), or vectors containing nucleotide sequences encoding siRNAs or miRNAs described herein, can be delivered to the CNS by local or systemic administration (e.g., via intrathecal, intraventricular, intraparenchymal, intranasal, intravenous, or subcutaneous administration) to treat diseases or conditions affecting the CNS, such as multiple sclerosis, Parkinson's disease, Huntington's disease, Alzheimer's disease, other chronic demyelinating diseases (e.g., neuromyelitis optica, CIDP), amyotrophic lateral sclerosis, chronic pain, stroke, allergic neuritis, progressive supranuclear palsy, Lewy body dementia (i.e., Lewy body dementia or Parkinson's dementia), frontotemporal dementia, corticobasal degeneration, traumatic brain injury, traumatic spinal cord injury, epilepsy, multiple system atrophy, chronic traumatic encephalopathy, Creutzfeldt-Jakob disease, glioblastoma, and leptomeningeal metastases.
[0096] The delivery of repressive RNA (e.g., siRNA) to cells described herein can be achieved in a variety of different ways. In vivo delivery can be performed by administering a composition containing repressive RNA to a subject, via local or systemic delivery, for example, via parenteral administration, such as subcutaneous, intravenous, or intramuscular administration.
[0097] In some implementations, the repressive RNA is associated with a delivery agent. A “delivery agent” is a substance or entity that is non-covalently or covalently associated with, or co-administered with, the repressive RNA, and that performs one or more functions that increase the stability and / or efficacy of the bioactive agent beyond levels that would be achieved if the bioactive agent were delivered (e.g., administered to a subject) without the delivery agent. For example, the delivery agent may protect the repressive RNA from degradation (e.g., in the bloodstream), may facilitate the entry of the repressive RNA into cells or into target cell compartments (e.g., the cytoplasm), and / or may enhance association with specific cells containing the molecular target to be regulated. Many delivery agents that can be used to deliver repressive RNA (e.g., siRNA) are known to those skilled in the art. See Kanasty, R. et al., Nat Mater. 12(11):967-77 (2013) for a review of some of these techniques. In some embodiments, for example, for systemic or local administration of repressive RNA, the repressive RNA may associate with a delivery agent (e.g., nanoparticles, dendritic polymers, polymers, liposomes, or cationic delivery systems). Without wishing to be bound by any theory, positively charged cationic delivery systems are thought to promote the binding of negatively charged repressive RNA and also enhance interactions at negatively charged cell membranes to allow for efficient cellular uptake of the repressive RNA. Lipids (e.g., cationic or neutral lipids), dendritic polymers, or polymers may bind to the repressive RNA or may form vesicles or micelles that encapsulate the repressive RNA. Methods for preparing and administering complexes comprising a cationic agent and repressive RNA are known in the art. In some embodiments, the use of any of the delivery agents described in U.S. Publication 20160298124 is particularly contemplated. In some embodiments, the repressive RNA forms a complex with cyclodextrin for systemic administration. In some embodiments, the repressive RNA is co-administered with lipids or lipid-containing particles. In some embodiments, the repressive RNA is administered in combination with a cationic polymer (which may be a peptide or a non-peptide polymer), lipid, peptide, PEG, cyclodextrin, or a combination thereof, wherein the cationic polymer, lipid, peptide, PEG, cyclodextrin, or combination thereof may be in the form of nanoparticles or microparticles. The lipids or peptides may be cationic. "Nanoparticle" refers to a particle with a length greater than 1 nanometer (nm) and less than about 150 nm (e.g., 20 nm–50 nm or 50 nm–100 nm) in two or three dimensions. "Microparticle" refers to a particle with a length greater than 150 nm and less than about 1000 nm in two or three dimensions. Nanoparticles may have covalently or non-covalently attached targeting portions and / or cell-penetrating portions or membrane-active portions.Nanoparticles, such as lipid nanoparticles, are described, for example, in Tatipari et al., Nanomaterials 7:77 (2017). Exemplary delivery agents, methods of manufacture, and uses in the delivery of repressive RNA are described in U.S. Patent Nos. 7,427,605; 8,158,601; 9,012,498; 9,415,109; 9,062,021; and 9,402,816. In some embodiments, delivery techniques known in the art as “Smarticles” are considered. In some embodiments, delivery techniques known in the art, namely “Stable Nucleic Acid Lipid Particles” (SNALP), are considered, wherein the nucleic acid to be delivered is encapsulated in a lipid bilayer containing a mixture of cationic lipids and fused lipids, and is also coated with a diffusible polyethylene glycol-lipid (PEG-lipid) conjugate that provides a neutral hydrophilic outer surface. In some embodiments, delivery may comprise quantum dots, silica nanoparticles, nanoemulsions, micelles, or EVs.
[0098] In some embodiments, the delivery agent comprises one or more amino alcohol cationic lipids, such as those described in U.S. Patent No. 9,044,512.
[0099] In some embodiments, the delivery agent comprises one or more amino acid lipids. An amino acid lipid is a molecule containing amino acid residues (e.g., arginine, homoarginine, norarginine, northoarginine, ornithine, lysine, homolysine, histidine, 1-methylhistidine, pyridylalanine, asparagine, N-ethylasparagine, glutamine, 4-aminophenylalanine, its N-methylated version, and derivatives thereof with modified side chains) and one or more lipophilic tails. Exemplary amino acid lipids and their use for delivering nucleic acids are described in U.S. Patent Application Publication No. 20110117125 and U.S. Patent Nos. 8,877,729, 9,139,554, and 9,339,461. In some embodiments, membrane-lytic poly(amidoamine) polymers and polyconjugates, such as those described in U.S. Patent Application Publication No. 20130289207, may be used. In some embodiments, the delivery agent comprises a lipopeptide compound containing a central peptide and having lipophilic groups attached to each end. In some embodiments, the lipophilic group may be derived from naturally occurring lipids. In some embodiments, the lipophilic group may comprise C(1-22)alkyl, C(6-12)cycloalkyl, C(6-12)cycloalkyl-alkyl, C(3-18)alkenyl, C(3-18)ynyl, C(1-5)alkoxy-C(1-5)alkyl, or dihydrosphingosine, or (2R,3R)-2-amino-1,3-octadecanediol, eicosadecanodihydrosphingosine, sphingosine, phytosphingosine, or cis-4-sphingosine. The central peptide may comprise a cationic or amphiphilic amino acid sequence. Examples of such lipopeptides and their use for delivering nucleic acids are described, for example, in U.S. Patent No. 9,220,785.
[0100] A “masking portion” refers to a molecule or group that, when physically associated with another agent (e.g., a polymer), shields, inhibits, or inactivates one or more properties (biophysical or biochemical characteristics) or activities of said agent. In some embodiments, the masking portion may be covalently or non-covalently attached to repressive RNA. The masking portion may be reversible, meaning that it attaches to the repressive RNA it masks via a reversible linker. As those skilled in the art will understand, a sufficient number of masking portions are attached to the repressive RNA to be masked to achieve the desired level of inactivation.
[0101] In some embodiments, the repressive RNA conjugate is used as a delivery agent for the polymer. Useful delivery polymers include, for example, poly(acrylate) polymers (see, for example, U.S. Patent Publication No. 20150104408), poly(vinyl ester) polymers (see, for example, U.S. Patent Publication No. 20150110732), and certain peptides. In some embodiments, the delivery polymer is a membrane-active polymer that is reversibly masked. In some embodiments, the repressive RNA or polymer, or both, has a targeting portion conjugated thereto. In some embodiments, the repressive RNA or the repressive RNA-targeting conjugate is co-administered with the delivery polymer, but not conjugated with the polymer. In this context, "co-administered" means administering the repressive RNA and the delivery polymer to a subject such that they are present in the subject during overlapping time periods. The repressive RNA-targeting conjugate and the delivery polymer may be administered simultaneously or sequentially. For simultaneous administration, they may be mixed before administration. For sequential administration, the repressive RNA or the delivery polymer may be administered first. The repressive RNA and delivery polymer can be administered in the same composition or separately, close enough in time, to enhance cytoplasmic delivery of the repressive RNA to the cell compared to cytoplasmic delivery that would occur without polymer administration. In some embodiments, the repressive RNA and delivery polymer are administered no more than 15, 30, 60, or 120 minutes apart. In some embodiments, the delivery polymer is a targeted, reversibly masked membrane-active polymer. The polymer has a targeting portion attached thereto that targets the polymer to the cell to which enhanced cytoplasmic delivery of the repressive RNA is desired. The repressive RNA can be targeted to the same cell, optionally using the same targeting portion; i.e., the repressive RNA can be administered as a repressive RNA-targeting portion conjugate. As used herein, the membrane-active polymer is a surface-active, amphiphilic polymer capable of inducing one or more of the following effects on biological membranes: membrane alteration or disruption, allowing non-membrane-permeable molecules to enter the cell or pass through the membrane, pore formation in the membrane, membrane rupture, or membrane disruption or dissolution. As used herein, the membrane or cell membrane comprises a lipid bilayer. Membrane alteration or disruption can be functionally defined by the activity of the polymer in at least one of the following assays: erythrocyte lysis (hemolysis), liposome leakage, liposome fusion, cell fusion, cell lysis, and endosome release. Membrane-active polymers can enhance polynucleotide delivery to cells by disrupting or destabilizing the plasma membrane or internal vesicle membranes (e.g., endosomes or lysosomes), for example, by forming pores in the membrane or disrupting endosome or lysosomal vesicles, thereby allowing the contents of the vesicles to be released into the cytoplasm. In some embodiments, the targeted, reversibly masked membrane-active polymer is an endosome-dissolving polymer.Endosome-dissolving polymers are polymers that, in response to pH changes, can cause the disruption or lysis of endosomes, or otherwise provide for the release of normally membrane-impermeable compounds (e.g., polynucleotides or proteins) from membrane-closed vesicles (e.g., endosomes or lysosomes). In some embodiments, the polymer is a reversibly modified amphiphilic membrane-active polyamine, wherein the reversible modification inhibits membrane activity, neutralizes the polyamine to reduce positive charge, and forms a near-neutral-charged polymer. Reversible modification can also provide cell-type-specific targeting and / or inhibition of non-specific polymer interactions. The polyamine can be reversibly modified by reversibly modifying an amine on the polyamine. The reversibly masked membrane-active polymer is substantially non-membrane-active during masking but becomes membrane-active upon demasking. The masking moiety is typically covalently bound to the membrane-active polymer via physiologically reversible linkages. By using physiologically reversible linkages, the masking moiety can be cleaved from the polymer in vivo, thereby demasking the polymer and restoring the activity of the demasked polymer. By selecting appropriate reversible connections, the activity of membrane-active polymers can be restored after the conjugate has been delivered or targeted to the desired cell type or cell location. The reversibility of the connection provides selective activation of the membrane-active polymer. Physiologically reversible bonds are reversible under mammalian cellular conditions, including chemical conditions such as pH, temperature, oxidative or reducing conditions or reagents found in or similar to those found in mammalian cells, and salt concentrations. In some embodiments, the targeting portion, such as the ASGPR targeting portion, can be used as a masking portion. In some embodiments, the ASGPR targeting portion has a lipophilic portion conjugated thereto. Exemplary targeting portions (e.g., ASGPR targeting portions), physiologically unstable bonds (e.g., enzyme unstable bonds, pH unstable bonds), masking portions, membrane-active polymers (e.g., endosome-dissolving active polymers), lipophilic portions, RNAi agent-targeting portion conjugates, delivery agent-targeting portion conjugates, conjugates comprising RNAi agents, targeting portions, and delivery agents, and methods for delivering nucleic acids to cells (e.g., hepatocytes) are described in U.S. Patent Application Publications Nos. 20130245091, 20130317079, 20120157509, 20120165393, 20120172412, 20120230938, 20140135380, 20140135381, 20150104408, and 20150110732. In some embodiments, the repressive RNA is co-administered with the melittin, for example, as described in U.S. Patent Application Publication No. 20120165393. The repressive RNA, the melittin, or both may have a targeting portion conjugated thereto, optionally via a reversible linker.In some embodiments, the masking portion comprises a dipeptide-amide benzyl carbonate or a disubstituted maleic anhydride masking portion, for example, as described in U.S. Patent Application Publication No. 20150110732.
[0102] In some embodiments, the repressive RNA can be administered in a “naked” form, i.e., in the absence of a delivery agent. The naked repressive RNA can be in a suitable buffer. The buffer may contain, for example, acetate, citrate, prolyl, carbonate, or phosphate, or any combination thereof. In some embodiments, the buffer is phosphate-buffered saline (PBS) or artificial cerebrospinal fluid. The pH and osmotic pressure of the buffer can be adjusted to make it suitable for administration to the subject. In some embodiments, the repressive RNA is not physically associated with lipids or lipid-containing particles. In some embodiments, the repressive RNA is not physically associated with nanoparticles or microparticles. In some embodiments, the repressive RNA is not physically associated with cationic polymers. In some embodiments, the repressive RNA is not physically associated with cyclodextrins. In some embodiments, the repressive RNA administered in a “naked” form contains a targeting moiety.
[0103] Repressive RNAs (such as siRNAs or miRNAs as described herein), or vectors containing nucleotide sequences encoding siRNAs or miRNAs as described herein, may be incorporated into pharmaceutical compositions. Such pharmaceutical compositions are particularly intended for administration and delivery to a subject, either in vivo or ex vivo. In some embodiments, the pharmaceutical composition also contains a pharmaceutically acceptable carrier or excipient. Such excipients include any pharmaceutical agent, such as one that does not induce an immune response harmful to the individual receiving the composition and can be administered without excessive toxicity. As used herein, the terms “pharmaceutically acceptable” and “physiologically acceptable” refer to biologically acceptable formulations (gaseous, liquid, or solid) or mixtures thereof suitable for one or more routes of administration, in vivo delivery, or contact. Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, glycerol, sugars, and ethanol. Pharmaceutically acceptable salts may also be included, such as inorganic acid salts like hydrochloride, hydrobromide, phosphate, sulfate, etc.; and salts of organic acids such as acetate, propionate, malonate, benzoate, etc. Non-limiting examples may include MgCl2, CaCl2, KCl, NaCl, and Na3PO4. Furthermore, such media may contain auxiliary substances, such as wetting agents or emulsifiers, pH buffers, etc.
[0104] The pharmaceutical composition may be provided in the form of a salt and can form with a variety of acids, including but not limited to hydrochloric acid, sulfuric acid, acetic acid, lactic acid, tartaric acid, malic acid, succinic acid, etc. Salts are often more soluble in water or other protic solvents than their corresponding free base forms. In some embodiments, the pharmaceutical composition may be a lyophilized powder.
[0105] Pharmaceutical compositions may comprise solvents (aqueous or non-aqueous), solutions (aqueous or non-aqueous), emulsions (e.g., oil-in-water or water-in-oil), suspensions, syrups, elixirs, dispersion and suspension media, coatings, isotonic agents, and absorption enhancers or delay agents compatible with drug administration or in vivo contact or delivery. Aqueous and non-aqueous solvents, solutions, and suspensions may include suspending agents and thickeners. Such pharmaceutically acceptable carriers include tablets (coated or uncoated), capsules (hard or soft), microbeads, powders, granules, and crystals. Complementary active compounds (e.g., preservatives, antibacterial agents, antiviral agents, and antifungal agents) may also be incorporated into the composition.
[0106] Pharmaceutical compositions can be formulated to be compatible with a particular route of administration or delivery, as described herein or known to those skilled in the art. Therefore, pharmaceutical compositions include carriers, diluents, or excipients suitable for administration via multiple routes.
[0107] Compositions suitable for parenteral or topical application may comprise aqueous and non-aqueous solutions, suspensions, or emulsions of the active compound. These formulations are typically sterile and is isotonic with the blood or other local biological fluids of the intended recipient. Non-limiting illustrative examples include water, buffered saline, Hank's solution, Ringer's solution, aCSF, glucose, fructose, ethanol, animal oils, vegetable oils, or synthetic oils. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Furthermore, suspensions of the active compound may be prepared as suitable oily injection suspensions. Suitable lipophilic solvents or mediators include fatty oils (such as sesame oil), or synthetic fatty acid esters (such as ethyl oleate or triglycerides), or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents that increase solubility to allow for the preparation of high-concentration solutions.
[0108] Cosolvents and adjuvants may be added to formulations. Non-limiting examples of cosolvents include hydroxyl groups or other polar groups, such as alcohols like isopropanol; glycols like propylene glycol, polyethylene glycol, polypropylene glycol, and glycol ethers; glycerol; polyoxyethylene alcohols and polyoxyethylene fatty acid esters. Adjuvants include, for example, surfactants such as soybean lecithin and oleic acid; sorbitan esters such as sorbitan trioleate; and polyvinylpyrrolidone.
[0109] After the pharmaceutical compositions are prepared, they can be placed in suitable containers and labeled for treatment. Such labeling may include dosage, frequency, and method of administration.
[0110] Pharmaceutical compositions and delivery systems suitable for the compositions, methods and uses of this disclosure are known in the art (see, for example, Remington: The Science and Practice of Pharmacy. 21st edition Philadelphia, Pa. Lippincott Williams & Wilkins, 2005).
[0111] This disclosure also provides methods for introducing repressive RNA (e.g., siRNA or miRNA as described herein) or a vector comprising a nucleotide sequence encoding the siRNA or miRNA described herein into cells or animals. In some embodiments, such methods include exposing a subject (e.g., cells or tissues of a subject) to the repressive RNA described herein (or a vector comprising a nucleotide sequence encoding the repressive RNA described herein) or administering the repressive RNA described herein (or a vector comprising a nucleotide sequence encoding the repressive RNA described herein) to a subject (e.g., a mammalian subject) such that the repressive RNA is expressed in the subject (e.g., in the subject's cells or tissues). In another embodiment, the method includes providing the repressive RNA described herein (or a vector comprising a nucleotide sequence encoding the repressive RNA described herein) to cells of an individual (a patient or subject, e.g., a mammal) such that the repressive RNA is expressed in the individual.
[0112] The composition of the repressive RNA described herein (or a vector comprising a nucleotide sequence encoding the repressive RNA described herein (e.g., an rAAV vector)) may be administered to a subject in need in a sufficient or effective amount. The dosage may vary and depend on the type, onset, progression, severity, frequency, duration, or probability of the disease being treated, the expected clinical endpoint, prior or concurrent treatments, the subject's general health condition, age, sex, race, or immunological capacity, and other factors that a person skilled in the art would recognize. The dosage, frequency, or duration may be increased or decreased proportionally as indicated by any adverse side effects, complications, or other risk factors of the treatment or therapy, and the subject's condition. A person skilled in the art will understand the factors that may affect the dosage and timing required to provide an amount sufficient to provide therapeutic or preventative benefit.
[0113] The dosage required to achieve a therapeutic effect, such as the vector genome / kg body weight dose (vg / kg) (e.g., in the case of vector-based delivery) or mg / kg body weight (mg / kg), will vary based on several factors, including but not limited to: the route of administration, the level of repressive RNA expression required to achieve a therapeutic effect, the specific disease being treated, any host immune response to the viral vector, the host immune response to the heterologous repressive RNA, and the stability of the expressed repressive RNA. Those skilled in the art can determine the rAAV / vector genome dosage range for treating patients with a specific disease or condition using vector-based repressive RNA delivery, based on the foregoing factors and others. Typically, the dosage range will be at least 1 × 10⁻⁶. 8 or more, for example, 1×10 9 1×10 10 1×10 11 1×10 12 1×10 13 1×10 14 Or more vector genomes per kilogram (vg / kg) of subject body weight to achieve therapeutic effects.
[0114] In some embodiments, the repressive RNA composition is administered to the subject in an amount between 0.01 mg / kg and 50 mg / kg. In some embodiments, the repressive RNA composition is administered at a dose of about 0.01 mg / kg to about 10 mg / kg or about 0.5 mg / kg to about 15 mg / kg. In some embodiments, the repressive RNA composition is administered at a dose of about 10 mg / kg to about 30 mg / kg. In some embodiments, the inhibitory RNA composition is administered at doses of about 0.1 mg / kg, about 0.3 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 1.5 mg / kg, about 2.0 mg / kg, about 2.5 mg / kg, about 3 mg / kg, about 3.5 mg / kg, about 4 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, or about 50 mg / kg. In some embodiments, the amount is between 0.01 mg / kg and 0.1 mg / kg, between 0.01 mg / kg and 0.1 mg / kg, between 0.1 mg / kg and 1.0 mg / kg, between 1.0 mg / kg and 2.5 mg / kg, between 2.5 mg / kg and 5.0 mg / kg, between 5.0 mg / kg and 10 mg / kg, between 10 mg / kg and 20 mg / kg, between 20 mg / kg and 30 mg / kg, between 30 mg / kg and 40 mg / kg, or between 40 mg / kg and 50 mg / kg. In some embodiments, a fixed dose is administered. In some embodiments, the dosage is between 1 mg and 1.0 g, for example, between 1 mg and 10 mg, between 10 mg and 20 mg, between 20 mg and 40 mg, between 40 mg and 80 mg, between 80 mg and 160 mg, between 160 mg and 320 mg, between 320 mg and 640 mg, or between 640 mg and 1 g. In some embodiments, the dosage is about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1000 mg. In some embodiments, the dosage is a daily dose.In some embodiments, the dosage is administered according to a dosing regimen with dosing intervals of at least 2 days, for example, at least 7 days, for example, about 2 weeks, 3 weeks, 4 weeks, 6 weeks, or 8 weeks. For example, in some embodiments, the inhibitory RNA composition is administered according to a dosing regimen with dosing intervals of at least 7 days. In some embodiments, the inhibitory RNA composition is administered once daily, weekly, monthly, every 2 months, 3 months, 4 months, 5 months, or 6 months or longer. In some embodiments, any of the dosages and / or dosing regimens described herein are administered subcutaneously. In some embodiments, the inhibitory RNA composition is administered once and the level of inhibition is subsequently measured, and once the level of inhibition decreases to a certain level, a subsequent dose of the inhibitory composition is administered.
[0115] In some embodiments, the subject exhibits sustained inhibition of C3, which is measured, for example, by C3 mRNA expression (e.g., in liver tissue, such as a liver biopsy), for at least 2 days, such as at least 7 days, for a period of time such as at least about 2, 3, 4, 6, 8, 10, 12, 16, or 20 weeks after administration. In some embodiments, the subject exhibits reduced C3 protein levels in a biological fluid or tissue, and said reduced C3 protein levels are maintained for a period of at least 2 days, such as at least 7 days, for example, for a period of time such as at least 2, 3, 4, 6, 8, 10, 12, 16, or 20 weeks after administration.
[0116] An effective or adequate amount may (but does not have to) be provided in a single administration, may require multiple administrations, and may (but does not have to) be administered alone or in combination with another composition (e.g., another complement inhibitor described herein). For example, the amount may be increased proportionally based on the subject's needs, the type, state, and severity of the disease being treated, or any side effects of the treatment (if any). An effective amount also includes amounts that result in a reduction in the use of another treatment, treatment regimen, or regimen (e.g., the administration of another complement inhibitor described herein).
[0117] Therefore, the pharmaceutical compositions of this disclosure include compositions in which the active ingredient is contained in an effective amount to achieve the intended therapeutic purpose. Using the techniques and guidance provided in this disclosure, determining the therapeutically effective dose is entirely within the capabilities of a skilled medical practitioner. The therapeutic dose may depend (among other factors) on the subject's age and general condition, the severity of the complement-mediated disease or condition, and the strength of the control sequence regulating the expression level of the repressive RNA described herein. Therefore, the therapeutically effective dose in humans will fall within a relatively wide range, which may be determined by a medical practitioner based on the individual patient's response to a vector-based treatment. The pharmaceutical composition may be delivered to a subject to allow the in vivo production of the repressive RNA described herein via gene- and / or cell-based therapies or via in vitro modification of patient or donor cells.
[0118] The methods and uses disclosed herein include systemic, regional, or local delivery and administration, or via any route, such as injection or infusion. In vivo delivery of pharmaceutical compositions can generally be accomplished by injection using a conventional syringe, although other delivery methods, such as convection-enhanced delivery, may also be used (see, for example, U.S. Patent No. 5,720,720). For example, the composition may be delivered subcutaneously, epidermally, intradermally, intrathecally, intraorbitally, intramucosa, intraperitoneally, intravenously, intrapleurally, intra-arterially, orally, intrahepatically, intraventricularly (e.g., via intraventricular injection), via the portal vein, or intramuscularly. Other modes of administration include oral and pulmonary administration, suppositories, and percutaneous application. Clinicians specializing in treating patients with complement-mediated conditions can determine the optimal route of administration for repressive RNA (e.g., siRNA or miRNA as described herein) or a vector containing a nucleotide sequence encoding the siRNA or miRNA described herein.
[0119] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) may be administered to the subject once daily, once weekly, every 2 weeks, 3 weeks, or 4 weeks, or even at longer intervals. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) may be administered according to a dosing regimen comprising (i) an initial administration once daily, once weekly, every 2 weeks, 3 weeks, or 4 weeks, or even at longer intervals; followed by (ii) a period of non-administration, such as 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 8 months, or 10 months, or 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years. In some embodiments, a vector comprising a nucleotide sequence encoding the repressive RNA described herein may be administered (i) once or more during an initial time period of up to 2 weeks, 4 weeks, or 6 weeks or less; followed (ii) for a period without administration, such as 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years. In some embodiments, the level of C3 expression and / or activity in the subject is monitored before and / or after treatment, for example, using an alternative pathway assay, a classic pathway assay, or both. Suitable assays are known in the art and include, for example, a hemolysis assay. In some embodiments, the subject is treated, or retreated, if the measured level of C3 expression and / or activity is 10%, 20%, 30%, 40%, 50%, 100%, 200%, or more higher than the measured level of C3 expression and / or activity in a control subject.
[0120] V. Diseases, symptoms, and signs In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) is administered to a subject who has or is at risk of complement-mediated damage to an organ, tissue, or cell. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) is administered in combination with one or more other complement inhibitors to a subject who has or is at risk of complement-mediated damage to an organ, tissue, or cell. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) is brought into contact with an organ, tissue, or cell in vitro. The organ, tissue, or cell may be introduced into the subject and may be protected from damage that would otherwise be caused by the complement system of the recipient.
[0121] Certain uses include: (1) protecting red blood cells (RBCs) from complement-mediated damage in individuals with conditions such as paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome or other conditions characterized by complement-mediated RBC hemolysis; (2) protecting transplanted organs, tissues, and cells from complement-mediated damage; (3) reducing ischemia / reperfusion (I / R) injury (e.g., in individuals suffering from trauma, vascular occlusion, myocardial infarction, or other conditions in which I / R injury may occur); and (4) protecting various body structures (e.g., the retina) or membranes (e.g., the synovium) that may be exposed to complement components from complement-mediated damage in any of a variety of different complement-mediated conditions. The beneficial effects of inhibiting complement activation on the surface of cells or other body structures are not limited to those effects directly resulting from protecting cells or structures themselves from direct complement-mediated damage (e.g., preventing cell lysis). For example, inhibiting complement activation can reduce the production of anaphylactic toxins and the resulting neutrophil influx / activation and other pro-inflammatory events, and / or reduce the potentially damaging release of intracellular contents, which may have beneficial effects on distal organ systems or the whole body.
[0122] A. Blood cell protection In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to protect blood cells from complement-mediated damage. Blood cells can be any cellular component of blood, such as red blood cells (RBCs), white blood cells (WBCs), and / or platelets. A variety of conditions are associated with complement-mediated damage to blood cells. Such conditions can be caused, for example, by a deficiency or defect in one or more of an individual's cells or soluble CRPs, for example, due to (a) mutations in genes encoding such proteins; (b) mutations in genes required to produce or function one or more CRPs; and / or (c) the presence of autoantibodies against one or more CRPs. Complement-mediated RBC cleavage can occur due to the presence of autoantibodies against RBC antigens, which may be generated from a variety of causes (often idiopathic). Individuals with such mutations in genes encoding CRPs and / or with antibodies against CRPs or against their own RBCs have an increased risk of conditions involving complement-mediated RBC damage. Individuals experiencing one or more characteristic episodes of the condition are at an increased risk of recurrence.
[0123] Paroxysmal nocturnal hemoglobinuria (PNH) is a relatively rare condition comprising acquired hemolytic anemia characterized by complement-mediated intravascular hemolysis, hemoglobinuria, bone marrow failure, and a tendency to thrombosis (a predisposition to blood clot formation). It is estimated to affect 16 people per million globally, occurs in both sexes, and can occur at any age, but often affects young adults (Bessler, M. & Hiken, J., Hematology Am Soc Hematol Educ Program, 104-110 (2008); Hillmen, P. Hematology Am Soc Hematol Educ Program, 116-123 (2008)). PNH is a chronic and debilitating disease with acute hemolytic episodes, leading to significant morbidity and shortened life expectancy. In addition to anemia, many patients experience abdominal pain, dysphagia, erectile dysfunction, and pulmonary hypertension, and have an increased risk of renal failure and thromboembolic events.
[0124] Paroxysmal nocturnal hemoglobinuria (PNH) was first described as a distinct entity in the 19th century, but the cause of hemolysis in PNH was not clearly identified until the 1950s with the discovery of alternative complement activation pathways (Parker C J. Paroxysmal nocturnal hemoglobinuria: an historical overview. Hematology Am Soc Hematol EducProgram. 93-103 (2008)). CD55 and CD59 are typically attached to the cell membrane via glycosylphosphatidylinositol (GPI) anchors (glycolipid structures that anchor certain proteins to the plasma membrane). PNH arises as a result of the non-malignant clonal expansion of hematopoietic stem cells that have acquired a somatic mutation in the PIGA gene, which encodes a protein involved in GPI anchor synthesis (Takeda J et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 73:703-711 (1993)). The progeny of these stem cells lack GPI-anchoring proteins, including CD55 and CD59. This deficiency makes these cells susceptible to complement-mediated RBC cleavage. Flow cytometry analysis using antibodies against GPI-anchoring proteins is commonly used for diagnosis. It detects the deficiency of cell surface GPI-anchored proteins and can determine the degree of deficiency and the proportion of cells affected (Brodsky R A. Advances in the diagnosis and therapy of paroxysmal nocturnalhemoglobinuria. Blood Rev. 22(2):65-74 (2008). PNH type III erythrocytes are completely lacking in GPI-linked proteins and are highly sensitive to complement, while PNH type II erythrocytes are partially lacking and less sensitive. FLAER is a fluorescently labeled inactive variant of proaerolysin (a bacterial toxin that binds to GPI anchors) and is increasingly used in conjunction with flow cytometry for the diagnosis of PNH. FLAER binding to granulocytopenia is sufficient to diagnose PNH. In some embodiments, the repressive RNA described herein (or a vector encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, protects PNH RBCs from C3b deposition.In some implementations, the repressive RNA described herein (or the vector encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, inhibits intravascular and extravascular hemolysis in subjects with PNH.
[0125] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) is administered alone or in combination with one or more other complement inhibitors described herein to subjects with atypical hemolytic uremic syndrome (aHUS). aHUS is a chronic condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, and is caused by inappropriate complement activation, usually due to mutations in genes encoding complement regulatory proteins (Warwicker, P., et al. Kidney Int 53, 836-844 (1998); Kavanagh, D. & Goodship, T. Pediatr Nephrol 25, 2431-2442 (2010)). Mutations in the complement factor H (CFH) gene are the most common genetic abnormality in patients with aHUS, and 60-70% of these patients die or reach end-stage renal failure within one year of disease onset (Kavanagh & Goodship, ibid.). Mutations in factors I, B, C3, factors H-related proteins 1-5, and thrombotic regulatory proteins have also been described. Other causes of aHUS include autoantibodies against complement regulatory proteins (e.g., CFH). In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to subjects identified as having mutations in factors I, B, C3, factors H-related proteins 1-5, or thrombotic regulatory proteins, or who have been identified as having antibodies against complement regulatory proteins (e.g., CFH).
[0126] Complement-mediated hemolysis occurs in a variety of other conditions, including autoimmune hemolytic anemia involving antibodies that bind to RBCs and cause complement-mediated hemolysis. For example, such hemolysis can occur in primary chronic cold agglutinin disease and in certain responses to drugs and other exogenous substances (Berentsen, S. et al., Hematology, 12, 361-370 (2007); Rosse, WF, Hillmen, P. & Schreiber, AD Hematology AmSoc Hematol Educ Program, 48-62 (2004)). In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to a subject who has or is at risk of chronic cold agglutinin disease. In another embodiment, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of HELLP syndrome, defined by the presence of hemolysis, elevated liver enzymes, and low platelet count, and is associated with mutations in complement regulatory proteins in at least a subset of subjects (Fakhouri, F., et al., 112:4542-4545 (2008)).
[0127] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to a subject who has or is at risk of warm antibody-type autoimmune hemolytic anemia.
[0128] In other embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) is used alone or in combination with one or more other complement inhibitors described herein to protect RBCs or other cellular components of blood to be infused into a subject. Examples of such uses are further discussed below.
[0129] B. Transplantation Transplantation is an increasingly important treatment method, providing a means of replacing organs and tissues damaged by trauma, disease, or other conditions. Kidneys, liver, lungs, pancreas, and heart are among the organs that can be successfully transplanted. Frequently transplanted tissues include bone, cartilage, tendons, cornea, skin, heart valves, and blood vessels. Islet transplantation or islet cell transplantation is a promising method for treating diabetes (e.g., type 1 diabetes). For the purposes of this disclosure, an organ, tissue, or cell (or cell population) to be transplanted, being transplanted, or already transplanted may be referred to as a "graft." For this purpose, blood transfusion is considered a "graft."
[0130] Transplantation exposes the graft to a variety of damaging events and stimuli that can lead to graft dysfunction and potential failure. For example, ischemia-reperfusion (I / R) injury is a common and significant cause of morbidity and mortality in many grafts, particularly solid organs, and can be a major determinant of graft survival. Transplant rejection is one of the major risks associated with transplantation between genetically different individuals and can lead to graft failure and the need for graft removal from the recipient.
[0131] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to protect the graft from complement-mediated damage. For example, a cell-responsive compressive statin analogue covalently attaches to the cellular response of the graft and inhibits complement activation. A cell-targeting compressive statin analogue binds to a target molecule in the graft (e.g., expressed by endothelial cells or other cells in the graft) and inhibits complement activation. The target molecule may be, for example, a molecule whose expression is induced or stimulated by a stimulus (such as injury or inflammation), a molecule that would be recognized as “non-self” by the recipient, a carbohydrate xenoantigen such as a blood group antigen or xenoantigen against which antibodies are normally present in humans, for example, a molecule containing an α-gal epitope. In some implementations, the reduction in complement activation can be demonstrated by the following: the reduction in mean C4d deposition in the blood vessels of grafts exposed to the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) alone or in combination with one or more other complement inhibitors described herein, compared to mean C4d deposition levels in grafts that have not been exposed to the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) alone or in combination with one or more other complement inhibitors described herein (e.g., in subjects matched for the graft and other treatments received).
[0132] In various embodiments of this disclosure, the graft may be contacted, either alone or in combination with one or more additional complement inhibitors described herein, before, during, and / or after transplantation, with a repressive RNA (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) that inhibits C3 expression. For example, prior to transplantation, the graft removed from the donor may be contacted with a liquid containing a cell-responsive, long-acting, or targeted compstatin analogue. For example, the graft may be soaked in the solution and / or perfused with the solution. In another embodiment, the repressive RNA (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more additional complement inhibitors described herein, is administered to the donor prior to graft removal. In some embodiments, the repressive RNA (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more additional complement inhibitors described herein, is administered to the recipient during and / or after graft introduction. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is locally delivered to the transplanted graft. In some embodiments, a cell-responsive, long-acting, or targeted compstatin analogue is administered systemically, such as intravenously or subcutaneously. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to the recipient prior to graft introduction. In some embodiments, the subject receives one or more additional doses of the repressive RNA, the vector encoding the repressive RNA, and / or one or more other complement inhibitors after graft reception.
[0133] This disclosure provides a composition comprising: (a) an isolated graft; and (b) a repressive RNA described herein that inhibits C3 expression (or a vector comprising a nucleotide sequence encoding the repressive RNA described herein). This disclosure also provides a composition comprising: (a) an isolated graft; (b) a cell-responsive, long-acting, or targeted compstatin analog; and (c) a repressive RNA described herein that inhibits C3 expression (or a vector comprising a nucleotide sequence encoding the repressive RNA described herein). In some embodiments, the composition further comprises a liquid solution suitable for contacting (e.g., for flushing, washing, soaking, perfusion, maintenance, or storage) a graft (e.g., an organ), such as an isolated graft that has been removed from a donor and is awaiting transplantation to a recipient. In some embodiments, this disclosure provides a composition comprising: (a) a liquid solution suitable for contacting a graft (e.g., an organ); and (b) a repressive RNA described herein that inhibits C3 expression (or a vector comprising a nucleotide sequence encoding the repressive RNA described herein). In some embodiments, the composition further comprises a cell-responsive, long-acting, or targeted compressatin analog. The liquid solution can be any physiologically acceptable to the graft (e.g., suitable osmotic composition, non-cytotoxic) and medically acceptable given the subsequent introduction of the graft into the recipient (e.g., preferably sterile or at least reasonably free of microorganisms or other contaminants) and compatible with cell-responsive compressatin analogs (i.e., does not impair the responsiveness of the compressatin analog) or with long-acting or targeted compressatin analogs. In some embodiments, the solution is any solution known in the art for any such purpose. In some embodiments, the liquid solution is Marshall or hypertonic citrate (Soltran®, Baxter Healthcare), University of Wisconsin (UW) solution (ViaSpan™, Bristol Myers Squibb), histidine tryptophan ketoglutarate (HTK) solution (Custodial®, Kohler Medical Limited), EuroCollins (Fresenius) and Celsior® (Sangstat Medical), Polysol, IGL-1, or AQIX® RS-1. Of course, other solutions may be used, such as solutions containing equivalent or similar components at the same or different concentrations, all within the physiologically acceptable range of compositions. In some embodiments, the solution does not contain components that a cellularly reactive compressive statin analog is expected to significantly respond to, and any solution may be modified or designed to lack such components.In some embodiments, the cell-responsive compstatin analogue is present in the graft-compatible solution at a concentration, for example, between 0.01 mg / ml and 100 mg / ml, or may be added to the solution to achieve such a concentration.
[0134] In some embodiments, the graft is or comprises: a solid organ, such as a kidney, liver, lung, pancreas, or heart. In some embodiments, the graft is or comprises: bone, cartilage, fascia, tendon, ligament, cornea, sclera, pericardium, skin, heart valve, blood vessel, amnion, or dura mater. In some embodiments, the graft comprises multiple organs, such as a heart-lung or pancreas-kidney graft. In some embodiments, the graft comprises fewer than a complete organ or tissue. For example, the graft may contain a portion of an organ or tissue, such as a liver lobe, blood vessel segment, skin flap, or heart valve. In some embodiments, the graft comprises a preparation containing isolated cells or tissue fragments that have been separated from their tissue source but retain at least some tissue structure (e.g., islets of Langerhans). In some embodiments, the preparation comprises isolated cells that are not attached to each other via connective tissue, such as hematopoietic stem cells or progenitor cells derived from peripheral blood and / or umbilical cord blood, or whole blood or any cell-containing blood product, such as red blood cells (RBCs) or platelets. In some implementations, the graft is obtained from a deceased donor (e.g., a brain-dead (DBD) or heart-dead donor). In other implementations, depending on the specific type of graft, the graft is obtained from a living donor. For example, kidneys, liver slices, and blood cells are types of grafts that can typically be obtained from a living donor without posing undue risks to the donor and in accordance with good medical practice.
[0135] In some embodiments, the graft is a xenograft (i.e., the donor and recipient are from different species). In some embodiments, the graft is an autograft (i.e., a graft from one site of the body to another site of the body from the same individual). In some embodiments, the graft is a syngenetic graft (i.e., the donor and recipient are genetically identical). In most embodiments, the graft is an allogeneic graft (i.e., the donor and recipient are genetically different members of the same species). In the case of an allogeneic graft, the donor and recipient may or may not be genetically related (e.g., family members). Typically, the donor and recipient have compatible blood types (at least ABO compatibility, and optionally Rh, Kell, and / or other blood cell antigen compatibility). The recipient's blood may have been screened for allogeneic antibodies against the graft and / or the recipient against the donor, as the presence of such antibodies can lead to hyperacute rejection (i.e., rejection that begins almost immediately after contact between the graft and the recipient's blood, e.g., within minutes). Complement-dependent cytotoxicity (CDC) assays can be used to screen for anti-HLA antibodies in a subject's serum. Serum is incubated with a panel of lymphocytes with a known HLA phenotype. If the serum contains antibodies against HLA molecules on target cells, complement-mediated lysis and cell death occur. Using a selected set of target cells allows for the attribution of specificity to the detected antibody. Other useful techniques for determining the presence or absence of anti-HLA antibodies and optionally their HLA specificity include ELISA assays, flow cytometry assays, and microbead array techniques (e.g., Luminex technology). Methods for performing these assays are well known in the art, and various kits for performing them are commercially available.
[0136] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, inhibits complement-mediated rejection. For example, in some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, inhibits hyperacute rejection. Hyperacute rejection is caused at least in part by antibody-mediated activation of the recipient complement system via the classical pathway and the resulting deposition of MAC on the graft. This is typically due to the presence of pre-existing antibodies in the recipient that react with the graft. While it is desirable to attempt to avoid hyperacute rejection through proper pre-transplant matching, this may not always be possible, for example, due to time and / or resource constraints. Furthermore, some recipients (e.g., multiple transfusion recipients, previous transplant recipients, women with multiple pregnancies) may already have so many pre-formed antibodies, possibly including antibodies against antigens that are not typically tested, that it is difficult or potentially nearly impossible to reliably obtain a compatible graft in a timely manner. Such individuals are at increased risk of hyperacute rejection.
[0137] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, inhibits acute rejection or graft failure. As used herein, “acute rejection” refers to rejection that occurs between at least 24 hours (usually at least several days to a week) and 6 months post-transplantation. Acute antibody-mediated rejection (AMR) typically involves an acute increase in donor-specific alloantibodies (DSA) in the first few weeks post-transplantation. Without being bound by any theory, it is possible that the conversion of pre-existing plasma cells and / or memory B cells to new plasma cells plays a role in the increased DSA production. Such antibodies can cause complement-mediated damage to the graft, which can be inhibited by exposing the graft to cellularly reactive compstatin analogs. Without being bound by any theory, inhibiting complement activation at the graft site reduces leukocyte (e.g., neutrophil) infiltration, another contributing factor to acute graft failure.
[0138] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, inhibits complement-mediated graft-versus-reperfusion injury. As discussed further below, graft-versus-reperfusion injury can occur during the reperfusion of tissues whose blood supply has been temporarily interrupted, as does in transplanted organs. Reducing graft-versus-reperfusion injury will decrease the likelihood or severity of acute graft dysfunction and reduce the likelihood of acute graft failure.
[0139] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, suppresses chronic rejection and / or chronic graft failure. As used herein, “chronic rejection or graft failure” refers to rejection or failure occurring at least 6 months post-transplantation (e.g., between 6 months and 1, 2, 3, 4, 5, or longer post-transplantation), typically following months to years of good graft function. This is caused by chronic inflammatory and immune responses against the graft. For the purposes of this document, chronic rejection may include chronic allogeneic graft vascular disease, a term used to refer to fibrosis of the internal blood vessels of the transplanted tissue. As immunosuppressive protocols have reduced the incidence of acute rejection, chronic rejection is becoming increasingly prominent as a cause of graft dysfunction and failure. Growing evidence suggests that B cell production of alloantibodies is a significant factor in the development of chronic rejection and graft failure (Kwun J. and Knechtle SJ, Transplantation, 88(8):955-61(2009)). Early damage to the graft can be a contributing factor to chronic processes such as fibrosis, which can eventually lead to chronic rejection. Therefore, inhibiting such early damage with cellularly reactive compstatin analogs can delay and / or reduce the likelihood or severity of chronic graft rejection.
[0140] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to the graft recipient to suppress graft rejection and / or graft failure.
[0141] C. Ischemia / reperfusion injury Ischemia-reperfusion (I / R) injury is a significant cause of tissue damage in post-traumatic conditions and other conditions associated with temporary interruptions of blood flow, such as myocardial infarction, stroke, severe infection, vascular disease, aneurysm repair, cardiopulmonary bypass, and transplantation.
[0142] In traumatic situations, systemic hypoxemia, hypotension, and localized disruption of blood supply caused by contusion, compartment syndrome, and vascular injury lead to ischemia, which damages metabolically active tissues. Restoration of blood supply triggers a strong systemic inflammatory response, which is often more harmful than the ischemia itself. Once the ischemic area is reperfused, locally produced and released factors enter the circulatory system and reach distant locations, sometimes causing significant damage to organs unaffected by the original ischemic injury (e.g., the lungs and intestines), leading to single-organ and multi-organ dysfunction. Complement activation occurs shortly after reperfusion and is a key mediator of post-ischemic injury, both directly and through its chemoattractant and stimulatory effects on neutrophils. All three major complement pathways are activated and, synergistically or independently, participate in I / R-related adverse events affecting numerous organ systems. In some embodiments of this disclosure, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to a subject who has recently (e.g., within the previous 2, 4, 8, 12, 24, or 48 hours) experienced trauma, such as trauma that puts the subject at risk of I / R injury, for example, due to systemic hypoxemia, hypotension, and / or local blood supply disruption. In some embodiments, a cell-responsive compstatin analogue may be administered intravascularly, optionally into a blood vessel supplying the injured body site or directly to the body site. In some embodiments, the subject has spinal cord injury, traumatic brain injury, burns, and / or hemorrhagic shock.
[0143] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to the subject before, during, or after a surgical procedure (e.g., a surgical procedure intended to temporarily interrupt blood flow to a tissue, organ, or body part). Examples of such procedures include cardiopulmonary bypass, angioplasty, heart valve repair / replacement, aneurysm repair, or other vascular surgeries. The repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, may be administered before, after, and / or during periods overlapping with the surgical procedure.
[0144] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to a subject with MI, thromboembolic stroke, deep vein thrombosis, or pulmonary embolism. The repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, may be administered in combination with thrombolytic agents such as tissue plasminogen activator (tPA) (e.g., alteplase, retavase, tenecteplase, eminase, streptokinase, or abbokinase). The repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, may be administered before, after, and / or during overlapping time periods with the thrombolytic agent.
[0145] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered to a subject to treat I / R injury.
[0146] D. Other complement-mediated diseases In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, may be administered systemically or introduced locally into the eye for the treatment of ocular conditions such as macular degeneration (e.g., age-related macular degeneration (AMD) and Staggart's macular dystrophy), diabetic retinopathy, glaucoma, or uveitis. For example, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, may be administered systemically, or introduced into the vitreous cavity (e.g., by intravitreal injection) or into the subretinal space (e.g., by subretinal injection) for the treatment of subjects who have or are at risk of AMD. In some embodiments, the AMD is neovascular (wet) AMD. In some embodiments, the AMD is dry AMD. As will be understood by those skilled in the art, dry AMD encompasses geographic atrophy (GA), intermediate AMD, and early AMD. In some embodiments, subjects with GA receive treatment to slow or stop the progression of the disease. For example, in some embodiments, treatment of a subject with GA reduces the rate of retinal cell death. The reduction in the rate of retinal cell death in patients treated with the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) alone or in combination with one or more other complement inhibitors described herein, compared to a control (e.g., a patient receiving a sham administration), can be evidenced by a reduced rate of GA lesion growth. In some embodiments, the subject has intermediate AMD. In some embodiments, the subject has early AMD. In some embodiments, a subject with intermediate or early AMD receives treatment to slow or halt disease progression. For example, in some embodiments, treatment of a subject with intermediate AMD can slow or halt progression to a late form of AMD (neovascular AMD or GA). In some embodiments, treatment of a subject with early AMD can slow or halt progression to intermediate AMD. In some embodiments, the eye has both GA and neovascular AMD. In some embodiments, the eye has GA but not wet AMD. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered into the choroidal space, for example, by choroidal injection, to treat eye conditions such as macular degeneration (e.g., age-related macular degeneration (AMD) and Staggart's macular dystrophy), diabetic retinopathy, glaucoma, or uveitis.In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is administered, for example, via intravitreal or subretinal injection, to treat glaucoma, uveitis (e.g., posterior uveitis), or diabetic retinopathy. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is introduced into the anterior chamber, for example, to treat anterior uveitis.
[0147] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) alone or in combination with one or more other complement inhibitors described herein is used to treat subjects who have or are at risk of an autoimmune disease (e.g., an autoimmune disease mediated at least in part by antibodies against one or more self-antigens).
[0148] The repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, may be introduced into the synovial cavity, for example, in subjects with arthritis (e.g., rheumatoid arthritis).
[0149] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of intracerebral hemorrhage.
[0150] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of myasthenia gravis (e.g., generalized myasthenia gravis), chronic inflammatory demyelinating polyneuropathy (CIDP), or multifocal motor neuropathy (MMN).
[0151] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of hidradenitis suppurativa.
[0152] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of immune-mediated necrotizing myopathy.
[0153] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of neuromyelitis optica (NMO).
[0154] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of a condition affecting the kidneys (e.g., the glomeruli of the kidneys). In some embodiments, the condition is membranoproliferative glomerulonephritis (MPGN), such as MPGN type I, MPGN type II, or MPGN type III. In some embodiments, the condition is IgA nephropathy (IgAN). In some embodiments, the condition is primary membranous nephropathy. In some embodiments, the condition is C3 glomerulonephropathy. In some embodiments, the condition is characterized by glomerular deposits containing one or more complement activation products (e.g., C3b) in the kidneys. In some embodiments, the treatment as described herein reduces the level of such deposits. In some embodiments, subjects with complement-mediated kidney disease have proteinuria (abnormally high levels of protein in the urine) and / or abnormally low glomerular filtration rate (GFR). In some implementations, the treatment described herein results in a reduction in proteinuria and / or an increase or stabilization of GFR.
[0155] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of developing neurodegenerative diseases. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of developing neuropathic pain. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of developing sinusitis or nasal polyps. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of developing cancer, including neurological cancers such as glioma, glioblastoma, and leptomeningeal diseases. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of sepsis. In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of adult respiratory distress syndrome.
[0156] In some embodiments, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat subjects who have or are at risk of allergic reactions or infusion reactions. For example, in some embodiments, the subject may be treated before, during, or after receiving a drug or medium that may cause an allergic reaction or infusion reaction. In some embodiments, subjects at risk of allergic reactions or who have allergic reactions to food (e.g., peanuts, shellfish, or other food allergens) or insect bites (e.g., bees, wasps) are treated with the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein.
[0157] The repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, may be administered locally or systemically in various embodiments of this disclosure.
[0158] In some implementations, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, is used to treat respiratory diseases.
[0159] In some aspects, methods are provided for treating complement-mediated conditions (e.g., chronic complement-mediated conditions), the methods comprising administering, to a subject requiring treatment of the condition, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein. In some aspects, methods are provided for treating Th17-related conditions, the methods comprising administering, to a subject requiring treatment of the condition, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein.
[0160] In some respects, a “chronic condition” is a condition that lasts for at least 3 months and / or is recognized in the art as a chronic condition. In many embodiments, a chronic condition lasts for at least 6 months, such as at least 1 year, or longer, such as indefinitely. Those skilled in the art will understand that at least some manifestations of a variety of chronic conditions can be intermittent and / or can fluctuate in severity over time. Chronic conditions can be progressive, for example, having a trend of becoming more severe or affecting a larger area over time. Many chronic complement-mediated conditions are discussed herein. A chronic complement-mediated condition can be any chronic condition in which complement activation (e.g., excessive or inappropriate complement activation) is involved, for example, as a contributing factor and / or at least a causative factor. For convenience, conditions are sometimes grouped by reference to organs or systems that are typically particularly affected in subjects suffering from said conditions. It should be understood that many conditions can affect multiple organs or systems, and such classification is by no means limiting. Furthermore, multiple manifestations (e.g., symptoms) may occur in subjects suffering from any of a variety of different diseases. Non-limiting information about the conditions of concern in this article can be found in, for example, standard internal medicine textbooks such as Cecil Textbook of Medicine (e.g., 23rd edition), Harrison's Principles of Internal Medicine (e.g., 17th edition), and / or standard textbooks focusing on specific medical areas, specific body systems or organs, and / or specific diseases.
[0161] In some embodiments, chronic complement-mediated disease is Th2-related disease. As used herein, Th2-related disease is characterized by an excessive number and / or excessive or inappropriate activity of Th2 subtype CD4+ helper T cells (“Th2 cells”) in the body or a part thereof (e.g., in at least one tissue, organ, or structure). For example, in at least one tissue, organ, or structure affected by the disease, there may be a Th2 cell predominance relative to Th1 subtype CD4+ helper T cells (“Th1 cells”). As is known in the art, Th2 cells typically secrete characteristic cytokines such as interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), while Th1 cells typically secrete interferon-7 (IFN-γ) and tumor necrosis factor β (TNF-α). In some implementations, Th2-related disease is characterized by the overproduction and / or amount of IL-4, IL-5 and / or IL-13, for example, relative to IFN-γ and / or TNF β, in at least some of at least one tissue, organ or structure.
[0162] In some implementations, chronic complement-mediated conditions are Th17-related conditions. In some aspects, as further described in PCT / US2012 / 043845, entitled “Methods for the Treatment of Chronic Conditions with Complement Inhibitors”, filed June 22, 2012, complement activation and Th17 cells participate in a cycle involving dendritic cells and antibodies, and this cycle helps maintain the pathological immune microenvironment that underlies a range of conditions. Without being bound by any theory, once established, the pathological immune microenvironment is self-sustaining and leads to cellular and tissue damage. In some aspects, long-acting comprustatin analogues can be used to treat Th17-related conditions.
[0163] As used herein, Th17-related disorders are characterized by an excessive number and / or excessive or inappropriate activity of Th17 subtype CD4+ helper T cells (“Th17 cells”) in the body or a part thereof (e.g., in at least one tissue, organ, or structure). For example, in at least one tissue, organ, or structure affected by the disorder, there may be a dominance of Th17 cells relative to Th1 and / or Th2 cells. In some embodiments, the dominance of Th17 cells is a relative dominance, for example, an increased ratio of Th17 cells to Th1 cells and / or an increased ratio of Th17 cells to Th2 cells relative to normal. In some embodiments, Th17 cells are associated with a higher ratio of regulatory T cells (CD4+ helper T cells). + CD25 +The ratio of regulatory T cells (also known as "Treg cells") is increased relative to normal. The formation and / or activation of Th17 cells are promoted by various cytokines, such as interleukin-6 (IL-6), interleukin-21 (IL-21), interleukin-23 (IL-23), and / or interleukin-1β (IL-1β). Th17 cell formation encompasses the differentiation of precursor T cells (e.g., naive CD4+ T cells) into the Th17 phenotype and their maturation into functional Th17 cells. In some embodiments, Th17 cell formation encompasses any aspect of Th17 cell development, proliferation (expansion), survival, and / or maturation. In some embodiments, Th17-related conditions are characterized by an overproduction and / or amount of IL-6, IL-21, IL-23, and / or IL-1β. Th17 cells typically secrete characteristic cytokines such as interleukin-17A (IL-17A), interleukin-17F (IL-17F), interleukin-21 (IL-21), and interleukin-22 (IL-22). In some embodiments, Th17-related symptoms are characterized by the overproduction and / or amount of Th17 effector cytokines (e.g., IL-17A, IL-17F, IL-21, and / or IL-22). In some embodiments, the overproduction or amount of cytokines is detectable in the blood. In some embodiments, the overproduction or amount of cytokines is detectable locally, for example, in at least one tissue, organ, or structure. In some embodiments, Th17-related symptoms are associated with a decrease in the number of Tregs and / or a decrease in the amount of Treg-related cytokines. In some implementations, Th17 disease is any chronic inflammatory disease; the term covers a range of disorders characterized by self-perpetuating immune damage to multiple tissues, and these disorders appear to be separate from the initial damage that caused the disorder (which may be unknown). In some implementations, Th17-related disease is any autoimmune disease. Many (if not most) “chronic inflammatory diseases” can actually be autoimmune diseases. Examples of Th17-related conditions include inflammatory skin diseases such as psoriasis and atopic dermatitis; systemic scleroderma and sclerosis; inflammatory bowel disease (IBD) (e.g., Crohn's disease and ulcerative colitis); Behçet's disease; dermatomyositis; polymyositis; multiple sclerosis (MS); dermatitis; meningitis; encephalitis; uveitis; osteoarthritis; lupus nephritis; rheumatoid arthritis (RA), Sjögren's syndrome, multiple sclerosis, vasculitis; inflammatory conditions of the central nervous system (CNS), chronic hepatitis; chronic pancreatitis, glomerulonephritis; sarcoidosis; thyroiditis; pathological immune responses to tissue / organ transplantation (e.g., transplant rejection); COPD, asthma, bronchiolitis, allergic pneumonia, idiopathic pulmonary fibrosis (IPF), periodontitis, and gingivitis.In some implementations, Th17 diseases are classic, known autoimmune diseases, such as type 1 diabetes or psoriasis. In some implementations, Th17-related conditions are age-related macular degeneration.
[0164] In some embodiments, chronic complement-mediated syndrome is an IgE-related syndrome. As used herein, "IgE-related syndrome" is a syndrome characterized by excessive and / or inappropriate production and / or quantity of IgE, excessive or inappropriate activity of IgE-producing cells (e.g., IgE-producing B cells or plasma cells), and / or excessive and / or inappropriate activity of IgE-responding cells (e.g., eosinophils or mast cells). In some embodiments, IgE-related syndrome is characterized by elevated levels of total IgE in the plasma and / or locally in the subject, and / or, in some embodiments, elevated levels of allergen-specific IgE.
[0165] In some embodiments, chronic complement-mediated disease is characterized by the presence of autoantibodies and / or immune complexes in the body, which can activate complement via, for example, the classical pathway. Autoantibodies can bind to self-antigens, for example, on cells or tissues in the body. In some embodiments, autoantibodies bind to antigens in blood vessels, skin, nerves, muscles, connective tissue, heart, kidneys, thyroid, etc. In some embodiments, the subject has neuromyelitis optica and produces autoantibodies against aquaporin 4 (e.g., IgG autoantibodies). In some embodiments, the subject has pemphigoid and produces autoantibodies against structural components of hemidesmosomes (e.g., transmembrane collagen XVII (BP180 or BPAG2) and / or thrombolysin family protein BP230 (BPAG1)) (e.g., IgG or IgE autoantibodies). In some embodiments, chronic complement-mediated disease is not characterized by autoantibodies and / or immune complexes.
[0166] In some implementations, chronic complement-mediated conditions are respiratory conditions. In some implementations, chronic respiratory conditions are asthma or chronic obstructive pulmonary disease (COPD). In some implementations, chronic respiratory conditions are pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis), radiation-induced lung injury, allergic bronchopulmonary aspergillosis, allergic pneumonia (also known as allergic alveolitis), eosinophilic pneumonia, interstitial pneumonia, sarcoidosis, Wegener's granulomatosis, or bronchiolitis obliterans. In some embodiments, this disclosure provides a method for treating a subject in need of a chronic respiratory condition (e.g., asthma, COPD, pulmonary fibrosis, radiation-induced lung injury, allergic bronchopulmonary aspergillosis, allergic pneumonia (also known as allergic alveolitis), eosinophilic pneumonia, interstitial pneumonia, sarcoidosis, Wegener's granulomatosis, or bronchiolitis obliterans), the method comprising administering, alone or in combination with one or more other complement inhibitors described herein, a repressive RNA (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) to the subject in need of treatment for the condition, either alone or in combination with one or more other complement inhibitors described herein.
[0167] In some embodiments, the chronic complement-mediated condition is allergic rhinitis, sinusitis, or nasal polyposis. In some embodiments, this disclosure provides a method of treating a subject requiring treatment for allergic rhinitis, sinusitis, or nasal polyposis, the method comprising administering, alone or in combination with one or more other complement inhibitors described herein, a repressive RNA (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) to the subject requiring treatment for the condition.
[0168] In some embodiments, chronic complement-mediated conditions are conditions affecting the musculoskeletal system. Examples of such conditions include inflammatory joint conditions (e.g., arthritis such as rheumatoid arthritis or psoriatic arthritis, juvenile chronic arthritis, spondyloarthritis, Reiter's syndrome, gout). In some embodiments, musculoskeletal system conditions cause symptoms such as pain, stiffness, and / or limited movement in the affected body parts. Inflammatory myopathy includes dermatomyositis, polymyositis, and various other conditions that are chronic inflammatory conditions of muscles of unknown etiology that lead to muscle weakness. In some embodiments, chronic complement-mediated conditions are myasthenia gravis. In some embodiments, this disclosure provides a method of treating any of the above-described conditions affecting the musculoskeletal system, the method comprising administering, alone or in combination with one or more other complement inhibitors described herein, the repressive RNA described herein to a subject requiring treatment for the condition.
[0169] In some implementations, chronic complement-mediated conditions are conditions affecting the skin system. Examples of such conditions include, for example, atopic dermatitis, psoriasis, pemphigoid, pemphigus, systemic lupus erythematosus, dermatomyositis, scleroderma, sclerodermomyositis, Sjögren's syndrome, and chronic urticaria. In some aspects, this disclosure provides a method of treating any of the above-described conditions affecting the skin system, the method comprising administering, alone or in combination with one or more other complement inhibitors described herein, a repressive RNA (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) to a subject requiring treatment for the condition.
[0170] In some implementations, chronic complement-mediated conditions affect the nervous system, such as the central nervous system (CNS) and / or peripheral nervous system (PNS). Examples of such conditions include, for example, multiple sclerosis, other chronic demyelinating diseases (e.g., neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy), amyotrophic lateral sclerosis, chronic pain, stroke, allergic neuritis, Huntington's disease, Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, Lewy body dementia (i.e., Lewy body dementia or Parkinson's dementia), frontotemporal dementia, traumatic brain injury, traumatic spinal cord injury, multiple system atrophy, corticobasal degeneration, epilepsy, chronic traumatic encephalopathy, Creutzfeldt-Jakob disease, glioma, glioblastoma, and leptomeningeal metastases. In some embodiments, this disclosure provides a method for treating any of the above-described conditions affecting the nervous system, the method comprising administering, alone or in combination with one or more other complement inhibitors described herein, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) to a subject requiring treatment for the condition.
[0171] In some embodiments, the chronic complement-mediated condition affects the circulatory system. For example, in some embodiments, the condition is vasculitis or other conditions associated with vascular inflammation, such as inflammation of blood vessels and / or lymphatic vessels. In some embodiments, the vasculitis is polyarteritis nodosa, Wegener's granulomatosis, giant cell arteritis, Churg-Strauss syndrome, microscopic polyangiitis, Henoch-Schonleinpurpura, Takayasu's arteritis, Kawasaki disease, or Behçet's disease. In some embodiments, the subject (e.g., a subject requiring treatment for vasculitis) is positive for anti-neutrophil cytoplasmic antibodies (ANCA).
[0172] In some embodiments, chronic complement-mediated conditions affect the gastrointestinal system. For example, the condition may be an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis. In some embodiments, this disclosure provides a method of treating chronic complement-mediated conditions affecting the gastrointestinal system, the method comprising administering, alone or in combination with one or more other complement inhibitors described herein, a repressive RNA (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) to a subject requiring treatment for the condition.
[0173] In some implementations, chronic complement-mediated conditions are thyroiditis (e.g., Hashimoto's thyroiditis, Graves' disease, postpartum thyroiditis), myocarditis, hepatitis (e.g., hepatitis C), pancreatitis, glomerulonephritis (e.g., membranoproliferative glomerulonephritis or membranous glomerulonephritis), or panniculitis.
[0174] In some embodiments, this disclosure provides a method for treating a subject suffering from chronic pain, the method comprising administering, alone or in combination with one or more additional complement inhibitors described herein, an inhibitory RNA (or a vector containing a nucleotide sequence encoding the inhibitory RNA described herein) to the subject in need, either alone or in combination with one or more additional complement inhibitors described herein. In some embodiments, the subject suffers from neuropathic pain. Neuropathic pain has been defined as pain caused or resulting from primary damage or dysfunction of the nervous system, particularly pain directly caused by lesions or diseases affecting the somatosensory system. For example, neuropathic pain may be caused by lesions involving somatosensory pathways and accompanied by damage to the small fibers of peripheral nerves and / or the spinothalamic-pituitary system in the CNS. In some embodiments, neuropathic pain originates from autoimmune diseases (e.g., multiple sclerosis), metabolic diseases (e.g., diabetes), infections (e.g., viral diseases such as herpes zoster or HIV), vascular diseases (e.g., stroke), trauma (e.g., injury, surgery), or cancer. For example, neuropathic pain can be pain that persists after the injury has healed or after stimulation of peripheral nerve endings has ceased, or pain caused by nerve damage. Exemplary symptoms of or associated with neuropathic pain include: painful diabetic neuropathy, postherpetic neuralgia (e.g., persistent or recurrent pain at the site of acute herpes zoster 3 months or longer after an acute attack), trigeminal neuralgia, cancer-related neuropathic pain, chemotherapy-related neuropathic pain, HIV-related neuropathic pain (e.g., pain from HIV neuropathy), central / post-stroke neuropathic pain, neuropathy associated with back pain, such as lower back pain (e.g., from radiculopathy such as spinal nerve root compression, such as lumbar nerve root compression, which may occur due to herniated disc), spinal stenosis, peripheral nerve injury pain, phantom limb pain, polyneuropathy, spinal cord injury-related pain, myelopathy, and multiple sclerosis. In some embodiments of this disclosure, the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein) is administered alone or in combination with one or more other complement inhibitors described herein, according to a dosing regimen, to treat neuropathic pain in a subject suffering from one or more of the above-described symptoms.
[0175] In some embodiments, chronic complement-mediated conditions are chronic ocular conditions. In some embodiments, chronic ocular conditions are characterized by macular degeneration, choroidal neovascularization (CNV), retinal neovascularization (RNV), ocular inflammation, or any combination thereof. Macular degeneration, CNV, RNV, and / or ocular inflammation may be defining and / or diagnostic features of the condition. Exemplary conditions are characterized by one or more of these features, including but not limited to macular degeneration-related symptoms, diabetic retinopathy, retinopathy of prematurity, proliferative vitreoretinopathy, uveitis, keratitis, conjunctivitis, and scleritis. Macular degeneration-related symptoms include, for example, age-related macular degeneration (AMD) and Staggart's macular dystrophy. In some embodiments, the subject is required to treat wet AMD. In some embodiments, the subject is required to treat dry AMD. In some embodiments, the subject is required to treat geographic atrophy (GA). In some embodiments, the subject is required to treat ocular inflammation. Ocular inflammation can affect numerous ocular structures, such as the conjunctiva (conjunctivitis), cornea (keratitis), outer sclera, sclera (scleritis), uveal canal, retina, vascular system, and / or optic nerve. Evidence of ocular inflammation may include the presence of inflammatory cells in the eye, such as white blood cells (e.g., neutrophils, macrophages), the presence of endogenous inflammatory mediators, and one or more symptoms such as eye pain, redness, photophobia, blurred vision, and floaters. Uveitis is a general term for inflammation of the uvea, including any structure of the uvea (including the iris, ciliary body, or choroid). Specific types of uveitis include iritis, iridocyclitis, cyclitis, plaque inflammation, and choroiditis. In some implementations, chronic ocular diseases are characterized by optic nerve damage (e.g., optic nerve degeneration), such as glaucoma.
[0176] In some embodiments, the methods disclosed herein inhibit (interfere with, disrupt) the DC-Th17-B-Ab-C-DC cycle discussed above. For example, administration of the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, can interrupt complement-stimulated DCs to promote the Th17 phenotype cycle. Consequently, the number and / or activity of Th17 cells are reduced, which in turn reduces the amount of Th17-mediated B cell stimulation and polyclonal antibody production. In some embodiments, these effects result in a “reset” of the immune microenvironment to a more normal, less pathological state. As described in Example 1 of PCT / US2012 / 043845 (WO / 2012 / 178083) and U.S. Publication No. 20140371133, evidence has been obtained in animal models of asthma supporting the ability of complement inhibition to prolong the inhibitory effect on Th17-related cytokines.
[0177] In some implementations, inhibition of the DC-Th17-B-Ab-C-DC cycle has a disease-modifying effect. Not wishing to be bound by any theory, and not merely to treat the symptoms of the condition, inhibition of the DC-Th17-B-Ab-C-DC cycle can interfere with underlying pathological mechanisms that can lead to ongoing tissue damage and / or disease exacerbation even when symptoms are well controlled. In some implementations, inhibition of the DC-Th17-B-Ab-C-DC cycle induces remission in chronic conditions. In some implementations, remission is defined as a state in which disease activity is absent or substantially absent in a subject with a chronic condition, with the possibility of disease relapse. In some implementations, remission can be prolonged for a period of time (e.g., at least 6 months, such as 6-12 months, 12-24 months, or longer) in the absence of continued treatment or with reduced doses or increased dosing intervals. In some aspects, complement inhibition can alter the immune microenvironment of Th17-rich tissues and modify it to be rich in regulatory T cells (Tregs). Doing so can allow the immune system to “reset” itself and enter a remission state. In some implementations, for example, remission can persist until a triggering event occurs. Triggering events can be, for example, infection (which may lead to the production of polyclonal antibodies that react both to infectious pathogens and to their own proteins), exposure to specific environmental conditions (e.g., high levels of air pollutants such as ozone or particulate matter or smoke components such as cigarette smoke, allergens), etc. Genetic factors can also play a role. For example, individuals with specific alleles in genes encoding complement components may have higher baseline levels of complement activity, a more reactive complement system, and / or lower baseline levels of endogenous complement regulatory protein activity. In some implementations, individuals have genotypes associated with an increased risk of AMD. For example, a subject may have polymorphisms in genes encoding complement proteins or complement regulatory proteins (e.g., CFH, C3, factor B) that are associated with an increased risk of AMD.
[0178] In some implementations, the immune microenvironment may gradually become more polarized toward the pathological state over time, for example, in subjects who have not yet developed symptoms of the chronic condition or in subjects who have developed the condition and have been treated as described herein. This shift can occur randomly (e.g., at least in part due to apparent random fluctuations in antibody levels and / or affinity) and / or as a result of cumulative “subthreshold” triggering events (those insufficient in strength to trigger a symptomatic outbreak of the condition).
[0179] In some embodiments, a shorter course of treatment with the repressive RNA described herein (or a vector containing a nucleotide sequence encoding the repressive RNA described herein), alone or in combination with one or more other complement inhibitors described herein, for example between 1 and 6 weeks, such as about 2-4 weeks, may provide a durable benefit. In some embodiments, remission is achieved over an extended period of time, such as 1-3 months, 3-6 months, 6-12 months, 12-24 months, or longer. In some embodiments, subjects may be monitored and / or treated prophylactically before symptom recurrence. For example, subjects may receive treatment before or at the time of exposure to a triggering event. In some embodiments, subjects may be monitored, for example, by monitoring for increases in biomarkers, such as indicators containing Th17 cells or Th17 cell activity or biomarkers of complement activation, and treatment may be initiated when the level of this biomarker increases. See, for example, PCT / US2012 / 043845 for further discussion.
[0180] VI. Combination Therapy In some aspects, the methods of this disclosure involve administering the repressive RNA described herein, alone or in combination with one or more other complement inhibitors. In some embodiments, the repressive RNA is administered to a subject who has already received treatment with another complement inhibitor; in some embodiments, the other complement inhibitor is administered to a subject who has received the repressive RNA. In some embodiments, both the repressive RNA and another complement inhibitor are administered to the subject.
[0181] In some implementations, administration of repressive RNA allows for the administration of a reduced dosing regimen (e.g., involving smaller amounts in individual doses, reduced dosing frequency, fewer doses, and / or reduced overall exposure) of the second complement inhibitor compared to administration of the second complement inhibitor as a monotherapy. Without wishing to be bound by any theory, in some implementations, the reduced dosing regimen of the second complement inhibitor can avoid one or more undesirable adverse reactions that would otherwise occur.
[0182] In some respects, the combined administration of repressive RNA and a second complement inhibitor can sufficiently reduce the amount of C3 in the subject's blood, enabling the dosing regimen that requires a reduction in the amount of repressive RNA and / or the second complement inhibitor to achieve the desired level of complement inhibition.
[0183] In some respects, the combined administration of an inhibitory RNA with a second complement inhibitor can sufficiently reduce the amount of C3 in the subject's blood, such that the required reduction in the dosing regimen of the inhibitory RNA and / or the second complement inhibitor achieves the desired level or amount of improvement in one or more signs, symptoms, biomarkers, or outcome indicators of complement-mediated disease. Any complement inhibitor, such as those known in the art, can be administered in combination with the inhibitory RNA described herein. In some embodiments, the complement inhibitor is a compressor or a compressor analogue.
[0184] Comparestatin is a cyclic peptide that binds to C3 and inhibits complement activation. As used herein, the term "comparstatin analogue" includes comparestatin and any complement-inhibiting analogues thereof. The term "comparstatin analogue" encompasses comparestatin and other compounds designed or identified based on comparestatin, wherein the complement-inhibiting activity is at least 50% of that of comparestatin (as measured using any complement activation assay accepted in the art or a substantially similar or equivalent assay). Certain suitable assays are described in the following: U.S. Patent No. 6,319,897, WO2004 / 026328, Moriis et al., ibid., Mallik, ibid., Katragadda 2006, ibid., WO2007062249 (PCT / US2006 / 045539); WO2007044668 (PCT / US2006 / 039397), WO / 2009 / 046198 (PCT / US2008 / 078593); and / or WO / 2010 / 127336 (PCT / US2010 / 033345). These assays may, for example, measure erythrocyte lysis mediated by alternative or classical pathways, or be an ELISA assay. In some embodiments, the assay described in WO / 2010 / 135717 (PCT / US2010 / 035871) is used.
[0185] Compstatin analogues can be prepared via the condensation of amino acid residues using a variety of synthetic methods known in the art for peptide synthesis, such as by expression in vitro or in living cells using methods known in the art, according to conventional peptide synthesis methods. For example, peptides can be synthesized using standard solid-phase methodologies as described in Malik (ibid.), Katragadda (ibid.), WO2004026328, and / or WO2007062249. Potentially reactive moieties, such as amino and carboxyl groups, reactive functional groups, etc., can be protected and subsequently deprotected using a variety of protecting groups and methods known in the art. See, for example, “Protective Groups in Organic Synthesis”, 3rd edition. Edited by Greene, TW and Wuts, PG, John Wiley & Sons, New York: 1999. Peptides can be purified using standard methods (e.g., reversed-phase HPLC). If desired, the separation of diastereomeric peptides can be performed using known methods such as reversed-phase HPLC. If desired, the formulation can be lyophilized and subsequently dissolved in a suitable solvent (e.g., water). The pH of the resulting solution can be adjusted using a base such as NaOH, for example, to physiological pH. If desired, the peptide formulation can be characterized by mass spectrometry, for example, to confirm mass and / or disulfide bond formation. See, for example, Mallik, 2005, and Katragadda, 2006.
[0186] Compathutine analogues can be modified by adding molecules such as polyethylene glycol (PEG) to stabilize the compound, reduce its immunogenicity, increase its lifespan in vivo, increase or decrease its solubility, and / or improve its resistance to degradation. PEGylation methods are well known in the art (Veronese, FM & Harris, Adv. Drug Deliv. Rev. 54, 453-456, 2002; Davis, FF, Adv. Drug Deliv. Rev. 54, 457-458, 2002); Hinds, KD & Kim, SW Adv. Drug Deliv. Rev. 54, 505-530 (2002; Roberts, MJ,Bentley, MD & Harris, JM Adv. Drug Deliv. Rev. 54, 459-476; 2002); Wang, YS et al. Adv. Drug Deliv. Rev.54, 547-570 (2002). Various polymers such as PEG and modified PEG, including derivatized PEG that can be readily attached to peptides, are described in Nektar Advanced Pegylation 2005-2006 Product Catalog, Nektar Therapeutics, San Carlos, Calif., which also provides details of appropriate conjugation procedures.
[0187] An exemplary PEGylated compatibilist analog is pegcetacoplan. Pegcetacoplan is also known as poly(oxy-1,2-ethylenedimethyl), α-hydro-ω-hydroxy-, and N-acetyl-L-isoleucyl-L-cysteyl-L-valine-1-methyl-L-tryptophanyl-L-glutamineyl-L-α-aspartyl-L-tryptophanyl-glycyl-L-alanyl-L-histyl-L-arginyl-L-cysteyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N 6 -Carboxy-L-lysine amide 15,15'-diester, cyclic (2->12)-(disulfide); or O,O'-bis[(S 2 ,S 12 -cyclo{N-acetyl-L-isoleucyl-L-cysteyl-L-valine-1-methyl-L-tryptophanyl-L-glutamineyl-L-α-aspartic-L-tryptophanylglycyl-L-alanyl-L-histyl-L-arginyl-L-cysteyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-L-lysamide})-N 6.15 [-carbonyl] polyethylene glycol (n=800-1100). Other compstatin analogues are described, for example, in WO 2012 / 155107 and WO 2014 / 078731.
[0188] In some embodiments, a composition comprising one or more repressive RNAs (e.g., siRNAs or miRNAs as described herein), or a composition comprising a vector encoding a nucleotide sequence of a siRNA or miRNA as described herein, is administered to a subject in combination with a compstatin analogue such that the compstatin analogue and / or the repressive RNA composition are administered at a lower frequency and / or at a lower dose.
[0189] In some embodiments, the complement inhibitor is an antibody, such as an anti-C3 and / or anti-C5 antibody or a fragment thereof. In some embodiments, the antibody fragment may be used to inhibit C3 or C5 activation. The fragmented anti-C3 or anti-C5 antibody may be Fab', Fab'(2), Fv, or single-chain Fv. In some embodiments, the anti-C3 or anti-C5 antibody is monoclonal. In some embodiments, the anti-C3 or anti-C5 antibody is polyclonal. In some embodiments, the anti-C3 or anti-C5 antibody is deimmunized. In some embodiments, the anti-C3 or anti-C5 antibody is a fully human monoclonal antibody. In some embodiments, the anti-C5 antibody is eculizumab. In some embodiments, the complement inhibitor is an antibody, such as an anti-C3 and / or anti-C5 antibody or a fragment thereof.
[0190] In some embodiments, complement inhibitors are peptide inhibitors and / or nucleic acid aptamers (see, for example, U.S. Publication No. 20030191084). Exemplary peptide inhibitors include enzymes that degrade C3 or C3b (see, for example, U.S. Patent No. 6,676,943). Other peptide inhibitors include microfactor H (see, for example, U.S. Publication No. 20150110766), derived from Staphylococcus aureus (…). Staphylococcus aureus Efb protein or complement inhibitor (SCIN) protein, or variants, derivatives or analogs thereof (see, for example, U.S. Publication 20140371133).
[0191] Various other complement inhibitors may also be used in various embodiments of this disclosure. In some embodiments, the complement inhibitor is a naturally occurring mammalian complement regulatory protein or a fragment or derivative thereof. For example, the complement regulatory protein may be CR1, DAF, MCP, CFH, or CFI. In some embodiments, the complement regulatory peptide is a peptide that is normally membrane-bound in its native state. In some embodiments, fragments of such peptides lacking some or all of their transmembrane and / or intracellular domains are used. For example, a soluble form of complement receptor 1 (sCR1) may also be used. For example, compounds called TP10 or TP20 (Avant Therapeutics) may be used. C1 inhibitors (C1-INH) may also be used. In some embodiments, a soluble complement control protein, such as CFH, is used.
[0192] C1s inhibitors can also be used. For example, U.S. Patent No. 6,515,002 describes compounds that inhibit C1s (furanyl and thiophenylamidine, heterocyclic amidine, and guanidine). U.S. Patent Nos. 6,515,002 and 7,138,530 describe heterocyclic amidines that inhibit C1s. U.S. Patent No. 7,049,282 describes peptides that inhibit classical pathway activation. In some embodiments, these peptides are identical or substantially identical to a portion of an IgG or IgM molecule. U.S. Patent No. 7,041,796 discloses a C3b / C4b complement receptor-like molecule and its use in inhibiting complement activation. U.S. Patent No. 6,998,468 discloses an anti-C2 / C2a inhibitor of complement activation. U.S. Patent No. 6,676,943 discloses a compound derived from Streptococcus pneumoniae (…). Streptococcus pneumoniae Human complement C3 degradation protein.
[0193] definition Antibody: As used herein, the term "antibody" refers to an immunoglobulin or a derivative thereof containing an immunoglobulin domain capable of binding an antigen. The antibody may be derived from any species, such as humans, rodents, rabbits, goats, chickens, etc. The antibody may be a member of any immunoglobulin class, including any human class: IgG, IgM, IgA, IgD, and IgE, or subclasses such as IgG1, IgG2, etc. In various embodiments of this disclosure, the antibody is a fragment such as Fab', F(ab')2, scFv (single-chain variable region), or other fragment retaining an antigen-binding site, or a recombinant scFv fragment, including recombinant fragments. See, for example, Allen, T., Nature Reviews Cancer, Vol. 2, 750-765, 2002, and its references. The antibody may be monovalent, bivalent, or multivalent. The antibody may be chimeric or "humanized" antibodies, wherein, for example, a variable domain of rodent origin is fused with a constant domain of human origin, thereby preserving the specificity of the rodent antibody. The human-originating domain need not be directly derived from humans in the sense that it was first synthesized in humans. Rather, the "human" domain can be generated in rodents whose genomes incorporate human immunoglobulin genes. See, for example, Vaughan et al., (1998), Nature Biotechnology, 16: 535-539. Antibodies can be partially or fully humanized. Antibodies can be polyclonal or monoclonal, though monoclonal antibodies are generally preferred for the purposes of this disclosure. Methods for generating antibodies that specifically bind to virtually any target molecule are known in the art. For example, monoclonal or polyclonal antibodies can be purified from the blood or ascites of the animal that produces the antibody (e.g., after natural exposure to the molecule or its antigenic fragments or after immunization with the molecule or its antigenic fragments), can be generated using recombinant techniques in cell culture or transgenic organisms, or can be prepared at least partially by chemical synthesis.
[0194] Approximately: As used herein, the term “approximately” or “about” when referring to a number is generally understood to include numbers falling within the range of 5%, 10%, 15%, or 20% in either direction (greater than or less than) of the number, unless otherwise stated or clearly indicated from the context (unless such a number would be less than 0% or more than 100% of the possible value).
[0195] Complementary: As used herein, "complementary" refers to the ability of specific bases, nucleosides, nucleotides, or nucleic acids to pair precisely. For example, adenine (A) and uridine (U) are complementary; adenine (A) and thymidine (T) are complementary; and guanine (G) and cytosine (C) are complementary, and are referred to in the art as Watson-Crick base pairing. If, when the strands are aligned in an antiparallel orientation, a nucleotide at a position in the first nucleic acid sequence is complementary to a nucleotide at a corresponding position in the second nucleic acid sequence, then the nucleotides form a complementary base pair, and the nucleic acids are complementary at that position. The percentage complementarity of the first and second nucleic acids can be assessed by aligning them in an antiparallel orientation to achieve maximum complementarity within an assessment window, determining the total number of nts in the two strands that form complementary base pairs within the window, dividing by the total number of nts within the window, and multiplying by 100. For example, AAAAAAAA and TTTGTTAT are 75% complementary because there are a total of 16 nts, of which 12 nts are in complementary base pairs. When calculating the number of complementary nts required to achieve a specific percentage of complementarity, the fraction is rounded to the nearest integer. A position occupied by a non-complementary nucleotide constitutes a mismatch, i.e., the position is occupied by a non-complementary base pair. In some embodiments, the evaluation window has the length described herein for the double-stranded portion or the target portion. Complementary sequences comprise polynucleotides containing a first nucleotide sequence and polynucleotides containing a second nucleotide sequence with base pairs across the entire length of both nucleotide sequences (if the lengths are the same) or across the entire length of the shorter sequence (if the lengths are different). Such sequences may be referred to herein as “perfectly complementary” (100% complementary) relative to each other. Nucleic acids that are at least 70% complementary on the evaluation window are considered “substantially complementary” on that window. In some embodiments, complementary nucleic acids are at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% complementary on the evaluation window. When this document refers to the first and second sequences as “substantially complementary,” the two sequences can be perfectly complementary, or they can contain one or more mismatched bases upon hybridization, for example, containing up to about 5%, 10%, 15%, 20%, or 25% mismatched bases upon hybridization, such as one, two, three, four, five, or six mismatched base pairs for a double strand of up to 30 base pairs, while retaining the ability to hybridize under conditions most relevant to its intended use. It should be understood that when two oligonucleotides are designed to form one or more single-stranded dangling overhangs after hybridization, such dangling overhangs are not considered mismatched or unpaired nucleotides for determining percentage complementarity.For example, a dsRNA consisting of two strands, one containing a 21-nucleotide oligonucleotide and the other a 23-nucleotide oligonucleotide, wherein the longer oligonucleotide contains a 21-nucleotide sequence that is perfectly complementary to the shorter oligonucleotide, plus a 2-nucleotide overhang, may be referred to herein as “perfectly complementary.” As used herein, a “complementary” sequence may include one or more non-Watson-Crick base pairs and / or base pairs formed from non-natural and other modified nucleotides, provided that the requirements related to their hybridization ability are met. Such non-Watson-Crick base pairs include, but are not limited to, G:U wobble base pairing or Hoogsteenbase pairing. Those skilled in the art will recognize that, according to the so-called "wobble" rule (see, for example, Murphy, FV IV & V Ramakrishnan, V., Nature Structural and Molecular Biology 11: 1251-1252 (2004)), guanine, cytosine, adenine, and uracil can be substituted with other bases without substantially altering the base-pairing properties of the polynucleotide containing the nucleotide carrying such bases. For example, a nucleotide containing inosine as its base can pair with a nucleotide containing adenine, cytosine, or uracil. Therefore, in the nucleotide sequence of the repressive RNA described herein, a nucleotide containing uracil, guanine, or adenine can be substituted with, for example, a nucleotide containing inosine. It should be understood that the terms “complementary,” “fully complementary,” and “substantially complementary” can be used for base matching between any two nucleic acids, such as base matching between the sense and antisense strands of dsRNA, or base matching between the antisense strand of ds repressive RNA (e.g., siRNA) and the target sequence, or base matching between an antisense oligonucleotide and the target sequence, as will be apparent from the context. As used herein, “hybridization” refers to the interaction between two nucleic acid sequences that contain or consist of complementary portions, such that a stable double-stranded structure is formed under specific purpose conditions, as will be understood by those skilled in the art.
[0196] Complement components: As used herein, the term "complement component" or "complement protein" is a molecule involved in the activation of the complement system or involved in one or more complement-mediated activities. Components of the classical complement pathway include, for example, the C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, C9, and the C5b-9 complex (also known as the membrane attack complex (MAC)) and active fragments or enzymatic cleavage products of any of the foregoing (e.g., C3a, C3b, C4a, C4b, C5a, etc.). Components of the alternative pathway include, for example, factors B, D, H, and I, and properdin, wherein factor H is a negative regulator of the pathway. Components of the lectin pathway include, for example, MBL2, MASP-1, and MASP-2. Complement components also include cell-binding receptors for soluble complement components. Such receptors include, for example, the C5a receptor (C5aR), the C3a receptor (C3aR), complement receptor 1 (CR1), complement receptor 2 (CR2), complement receptor 3 (CR3), etc. It should be understood that the term "complement component" is not intended to include molecules and molecular structures that act as "triggers" for complement activation, such as antigen-antibody complexes, foreign structures present on microorganisms or artificial surfaces, etc.
[0197] Host cell: As used herein, the term "host cell" refers to a cell into which exogenous DNA (recombinant or otherwise) has been introduced. Those skilled in the art will understand upon reading this disclosure that these terms refer not only to a specific subject cell but also to its offspring. Because certain modifications may occur in offspring due to mutations or environmental influences, these offspring may actually differ from the parent cell but are still included within the scope of the term "host cell" as used herein. In some embodiments, the host cell includes prokaryotic and eukaryotic cells selected from any living organism suitable for expressing exogenous DNA (e.g., recombinant nucleic acid sequences). Exemplary cells include prokaryotic and eukaryotic (unicellular or multicellular) cells, bacterial cells (e.g., strains of *Escherichia coli*, *Bacillus* species, *Streptomyces* species, etc.), mycobacterial cells, fungal cells, yeast cells (e.g., *Saccharomyces cerevisiae*, *Schizosaccharomyces cerevisiae*, *Pichia pastoris*, *Pichia pastoris*, etc.), plant cells, insect cells (e.g., SF-9, SF-21, baculovirus-infected insect cells, *Spodoptera litura*, etc.), non-human animal cells, human cells, or cell fusions, such as hybridomas or tetrad hybridomas. In some embodiments, the cells are human, monkey, ape, hamster, rat, or mouse cells. In some embodiments, the cells are eukaryotic cells and are selected from the following: CHO (e.g., CHOK1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cells, Vero, CV1, kidney cells (e.g., HEK293, 293 EBNA, MSR 293, MDCK, HaK, BHK), HeLa, HepG2, W138, MRC 5, Colo205, HB 8065, HL-60 (e.g., BHK21), Jurkat, Daudi, A431 (epidermal), CV-1, U937, 3T3, L cells, C127 cells, SP2 / 0, NS-0, MMT 060562, testicular Sertoli cells, BRL 3A cells, HT1080 cells, myeloma cells, tumor cells, and cell lines derived from the above cells. In some embodiments, the cells contain one or more viral genes.
[0198] Identity: As used herein, the term "identity" refers to the overall relevance between polymer molecules, such as nucleic acid molecules (e.g., DNA and / or RNA molecules) and / or polypeptide molecules. In some embodiments, polymer molecules are considered "substantially identical" to each other if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. For example, the percentage of identity between two nucleic acid or polypeptide sequences can be calculated by comparing the two sequences for optimal comparison purposes (e.g., vacancies can be introduced in one or both of the first and second sequences to achieve optimal alignment, and dissimilar sequences can be ignored for comparison purposes). In some embodiments, the length of the sequence compared for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. Nucleotides at the corresponding positions are then compared. The molecules are considered identical at a position in the first sequence when that position is occupied by the same residue (e.g., a nucleotide or amino acid) as the corresponding position in the second sequence. The percentage of identity between two sequences is a function of the number of common positions shared by the sequences, taking into account the number of vacancies introduced for optimal alignment of the two sequences and the length of each vacancy. Sequence comparisons and the determination of the percentage of identity between two sequences can be accomplished using mathematical algorithms. For example, the Meyers and Miller algorithm (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0), can be used to determine the percentage of identity between two nucleotide sequences. In some exemplary embodiments, nucleic acid sequence comparisons using the ALIGN program employ a PAM120 weighted residue table, a vacancy length penalty of 12, and a vacancy penalty of 4. Alternatively, the percentage of identity between two nucleotide sequences can be determined using the GAP program in the GCG software package using the NWSgapdna.CMP matrix.
[0199] Linkage: As used herein, the term "linkage" when referring to two or more parts means that these parts are physically associated or connected to each other to form a sufficiently stable molecular structure such that the parts remain bound under the conditions for forming the link, and preferably under the conditions of using a new molecular structure, such as physiological conditions. In some preferred embodiments of this disclosure, the link is a covalent link. In other embodiments, the link is non-covalent. Parts may be directly or indirectly linked. When two parts are directly linked, they are covalently bonded to each other or sufficiently close together such that intermolecular forces between the two parts maintain their association. When two parts are indirectly linked, each of them is covalently or non-covalently connected to a third part, which maintains the association between the two parts. Typically, when two parts are referred to as being linked by a "joint," "linking moiety," or "linking portion," the connection between the two linking portions is indirect, and typically each of the linked portions is covalently bonded to the joint. The connector can be any suitable part that, within a reasonable time period, under conditions consistent with the stability of the part (which may be appropriately protected according to the conditions), and in a sufficient quantity, reacts with the two parts to be connected to produce a reasonable yield.
[0200] MicroRNA (miRNA): As used herein, the term “microRNA” or “miRNA” refers to a small non-coding RNA molecule that can play a role in the transcriptional and / or post-transcriptional regulation of target gene expression. These terms encompass mature miRNA sequences or precursor miRNA sequences, including primary transcripts (pri-miRNA) and stem-loop precursors (pre-miRNA). The biogenesis of naturally occurring miRNAs begins in the cell nucleus, where they are transcribed by RNA polymerase II to produce primary transcripts (pri-miRNA). The primary transcript is cleaved by Drosha ribonuclease III to produce a stem-loop precursor miRNA (pre-miRNA) of approximately 70 nt. The precursor miRNA is then actively exported to the cytoplasm, where it is cleaved by Dicer ribonuclease to form mature miRNA, which includes an “antisense strand” or “guide strand” (which includes a region substantially complementary to the target sequence) and a “sense strand” or “passenger strand” (which includes a region substantially complementary to the antisense strand region). Those skilled in the art will understand that the guide strand can be perfectly complementary to the target region of the target RNA, or it can have less than perfect complementarity to the target region of the target RNA. The guide strand of the miRNA is incorporated into an RNA-induced silencing complex (RISC), which recognizes the target mRNA by base pairing with the miRNA and typically results in translational repression or destabilization of the target mRNA. As understood in the art, for naturally occurring miRNAs, target mRNA recognition occurs through incomplete base pairing with the mRNA. In some embodiments, the miRNA is synthetic or engineered, and target mRNA recognition occurs through perfect base pairing with the mRNA. Typically, the target mRNA contains a sequence complementary to the miRNA's "seed" sequence, which typically corresponds to nucleotides 2-8 of the miRNA. Information about miRNAs and related pri-miRNAs and pre-miRNA sequences is available in miRNA databases (such as miRBase (Griffiths-Jones et al., 2008, Nucl Acids Res 36, (Database Issue: D154-D158)) and the NCBI Human Genome Database.
[0201] Operablely Connected: As used herein, the term "operably connected" refers to a juxtaposition in which the components are in a relationship that allows them to function in their intended manner. Control elements "operably connected" to functional elements are associated in such a manner that the expression and / or activity of the functional element is realized under conditions compatible with the control element. In some embodiments, the "operably connected" control element is sequential (e.g., covalently connected) to the target encoding element; in other embodiments, the control element operates in a trans or otherwise manner at a location derived from the target functional element.
[0202] Recombinant: As used herein, the term "recombinant" is intended to refer to polypeptides designed, engineered, prepared, expressed, produced, manufactured, and / or isolated by recombinant means, such as polypeptides expressed using a recombinant expression vector transfected into host cells; polypeptides isolated from recombinant human polypeptide libraries; polypeptides isolated from animals (e.g., mice, rabbits, sheep, fish, etc.) where the animal is transgenic or manipulated to express a gene or genomic element encoding and / or instructing the expression of the polypeptide or one or more components, portions, elements, or domains thereof; and / or polypeptides prepared, expressed, produced, or isolated by any other means involving splicing or linking selected nucleic acid sequence elements to each other, chemically synthesizing selected sequence elements, and / or otherwise producing nucleic acids encoding and / or instructing the expression of the polypeptide or one or more components, portions, elements, or domains thereof. In some embodiments, one or more of such selected sequence elements are present in nature. In some embodiments, one or more of such selected sequence elements are designed by computer simulation. In some implementations, one or more of these selected sequence elements are derived from the mutagenesis (e.g., in vivo or in vitro) of known sequence elements (e.g., from a lineage of the target source organism (e.g., human, mouse, etc.)).
[0203] RNA Interference: As used herein, the term “RNA interference” or “RNAi” generally refers to a process in which double-stranded RNA molecules or short hairpin RNA molecules reduce or inhibit the expression of nucleic acid sequences that are substantially or completely homologous to said double-stranded or short hairpin RNA molecules. Without wishing to be bound by any theory, it is believed that in nature, the RNAi pathway is initiated by a type III endonuclease called Dicer, which cleaves long double-stranded RNA (dsRNA) into double-stranded fragments typically 21-23 base pairs with 2-base 3' overhangs (although variations in length and overhangs (e.g., 1, 2, 3, 4, 5, and more than 5 overhangs) are also considered), which are referred to as “short interfering RNA” (“siRNA”). Such siRNAs comprise two single-stranded RNAs (ssRNAs) having an "antisense strand" or "guide strand" and a "sense strand" or "passenger strand." The antisense strand or guide strand includes a region substantially complementary to the target sequence, and the sense strand or passenger strand includes a region substantially complementary to the region of the antisense strand. Those skilled in the art will understand that the guide strand may be fully complementary to the target region of the target RNA, or it may have less than full complementarity to the target region of the target RNA.
[0204] Subject: As used herein, the term "subject" or "test subject" refers to any organism to which the provided compound or composition is administered according to this disclosure, for example, for experimental, diagnostic, preventative, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; etc.) and plants. In some embodiments, the subject may have and / or be susceptible to diseases, conditions, and / or symptoms.
[0205] Essentially: As used herein, the term “essentially” refers to a qualitative condition that exhibits the complete or near-complete degree or range of a desired characteristic or property. Those skilled in the art of biology will understand that biological and chemical phenomena rarely (if at all) complete and / or continue to complete or achieve or avoid absolute results. Therefore, the term “essentially” is used herein to capture the inherent lack of completeness in many biological and / or chemical phenomena.
[0206] Suffering from: an individual who is diagnosed with a disease, condition and / or symptom and / or exhibits one or more symptoms of a disease, condition and / or symptom.
[0207] Target gene: As used herein, a “target gene” refers to a gene whose expression is to be regulated (e.g., repressed). As used herein, the term “target RNA” refers to RNA to be degraded or translated repressed or otherwise repressed by one or more miRNAs. Target RNA may also be referred to as a target sequence or target transcript. The RNA may be a primary RNA transcript (e.g., pre-mRNA) transcribed from a target gene or a processed transcript, such as mRNA encoding a polypeptide. As used herein, the terms “target moiety” or “target region” refer to a continuous portion of the nucleotide sequence of the target RNA. In some embodiments, the target moiety of the mRNA is at least long enough to serve as a substrate for RNA interference (RNAi)-mediated cleavage within that moiety in the presence of a suitable repressive RNA. The length of the target moiety may be about 8-36 nucleotides, for example, about 10-20 or about 15-30 nucleotides. The length of the target moiety may have specific values or subranges within the aforementioned ranges. For example, in some embodiments, the length of the target portion can be approximately 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-2 Between 9, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides.
[0208] Therapeutic agent: As used herein, the phrase “therapeutic agent” means any agent that, when administered to a subject, has a therapeutic effect and / or induces the desired biological and / or pharmacological effect. In some embodiments, a therapeutic agent is any substance that can be used to reduce, improve, alleviate, inhibit, prevent, delay the onset, reduce the severity and / or reduce the incidence of symptoms or features of one or more diseases, conditions and / or ailments.
[0209] Therapeutic Effective Amount: As used herein, the term "therapeutic effective amount" means the amount of a substance (e.g., a therapeutic agent, composition, and / or formulation) that, when administered as part of a treatment regimen, elicits a desired biological response. In some embodiments, a therapeutically effective amount of a substance is an amount sufficient to treat, diagnose, prevent, and / or delay the onset of a disease, condition, and / or symptom when administered to a subject who has or is susceptible to such a disease, condition, and / or symptom. As will be understood by those skilled in the art, the effective amount of a substance can depend on factors such as the desired biological endpoint, the substance to be delivered, and the target cells or tissues. For example, an effective amount of a compound in a formulation for treating a disease, condition, and / or symptom is an amount that reduces, improves, alleviates, inhibits, prevents, delays the onset, reduces the severity, and / or reduces the occurrence of one or more symptoms or signs of the disease, condition, and / or symptom. In some embodiments, the therapeutically effective amount is administered in a single dose; in some embodiments, multiple unit doses are required to deliver the therapeutically effective amount.
[0210] Treatment: As used herein, the term “treatment” means providing treatment, i.e., providing any type of medical or surgical management to a subject. Treatment may be provided to reverse, alleviate, or inhibit the progression of a disease, condition, or disorder, prevent or reduce the likelihood of a disease, condition, or disorder, or to reverse, alleviate, inhibit, or prevent the progression of one or more symptoms or manifestations of a disease, condition, or disorder, or to prevent or reduce the likelihood of a disease, condition, or disorder. “Prevention” means preventing a disease, condition, condition, or symptom or manifestation from occurring in at least some individuals for at least a period of time. Treatment may include administering an agent to a subject after the appearance of one or more symptoms or manifestations of a complement-mediated condition, for example, to reverse, alleviate, reduce the severity and / or inhibit or prevent the progression of the condition and / or to reverse, alleviate, reduce the severity and / or inhibit or prevent one or more symptoms or manifestations of the condition. The compositions of this disclosure may be administered to subjects who have developed a complement-mediated condition or who are at increased risk of developing such a condition relative to members of the general population. The compositions of this disclosure may be administered prophylactically, i.e., before the appearance of any symptoms or manifestations of said condition. In such cases, the subject is typically at risk of developing the aforementioned condition.
[0211] Nucleic acids: The term "nucleic acid" includes any nucleotide, its analogues, and polymers thereof. As used herein, the term "polynucleotide" refers to a polymeric form of nucleotides (ribonucleotides (RNA) or deoxyribonucleotides (DNA)) of any length. These terms refer to the primary structure of a molecule and therefore include double-stranded and single-stranded DNA, as well as double-stranded and single-stranded RNA. As equivalents, these terms include RNA or DNA analogues made from nucleotide analogues and modified polynucleotides (e.g., but not limited to methylated, protected, and / or capped nucleotides or polynucleotides). In some embodiments, the siRNA of the present invention may contain a 5' cap, such as a vinylphosphonate, on the antisense strand. These terms encompass polynucleotides or oligonucleotides (RNA) and polydeoxynucleotides or oligodeoxynucleotides (DNA); RNA or DNA derived from N-glycosides or C-glycosides of nucleotides and / or modified nucleotides; nucleic acids derived from sugars and / or modified sugars; and nucleic acids derived from phosphate bridges and / or modified phosphorus bridges (also referred to herein as "nucleotide linkages"). These terms cover nucleic acids containing any combination of nucleotides, modified nucleotides, sugars, modified sugars, phosphate bridges, or modified phosphorus bridges. Examples include, but are not limited to, nucleic acids containing a ribose moiety, nucleic acids containing a deoxyribose moiety, nucleic acids containing both ribose and deoxyribose moieties, and nucleic acids containing both ribose and modified ribose moieties. In some embodiments, the prefix poly- refers to nucleic acids containing 2 to about 10,000, 2 to about 50,000, or 2 to about 100,000 nucleotide monomer units. In some implementations, the prefix oligo- refers to a nucleic acid containing 2 to approximately 200 nucleotide monomer units.
[0212] Vector: As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is the "plasmid," which is a circular double-stranded DNA loop in which an additional DNA segment can be linked. Another type of vector is the viral vector, in which an additional DNA fragment can be linked into the viral genome. Some vectors are capable of autonomous replication in the host cell to which they are introduced (e.g., bacterial vectors with bacterial origins of replication and attachable mammalian vectors). Other vectors (e.g., non-attached mammalian vectors) can be integrated into the host cell's genome after introduction into the host cell, thereby replicating along with the host genome. Furthermore, some vectors can direct the expression of genes operatively linked to them. Such vectors are referred to herein as "expression vectors."
[0213] Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipid transfection). Enzymatic reactions and purification techniques can be performed according to the manufacturer's instructions or as is commonly done in the art or as described herein. The foregoing techniques and procedures can generally be performed according to conventional methods well known in the art and as described in the various general and more specific references cited and discussed throughout this specification. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)), which is incorporated herein by reference for any purpose.
[0214] All publications, patent applications, patents, and other references mentioned herein, including GenBank accession numbers, are incorporated herein by reference in their entirety. Furthermore, materials, methods, and examples are illustrative only and not intended to be limiting. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. While similar or equivalent methods and materials may be used in the practice or testing of this invention, suitable methods and materials are described herein.
[0215] Other exemplary implementations One embodiment is a separate, modified sequence comprising any one of SEQ ID NO: 50-153 or 209-327 (i.e., any one of the antisense sequences in Table 1B or Table A-2). Such a separate, modified sequence may further comprise at least one ligand attached to either the 5' or 3' end, wherein each ligand is independently selected from the group consisting of: GalNAc moieties, C16 lipids, and C18 lipids. Such ligands may be attached to the sequence via a linker.
[0216] One embodiment is a separate, modified sequence comprising any one of SEQ ID NO: 29-49 or 154-208 (i.e., any one of the positive-sense sequences in Table 1B or Table A-2). Such a separate, modified sequence may further comprise at least one ligand attached to either the 5' or 3' end, wherein each ligand is independently selected from the group consisting of GalNac moieties, C16 lipids, and C18 lipids. Such ligands may be attached to the sequence via a linker.
[0217] One embodiment is an siRNA comprising an antisense strand and a sense strand, wherein the antisense strand comprises a nucleobase sequence containing any one of SEQ ID NO: 50-153 or 209-327 (i.e., any one of the antisense strand sequences in Table 1B or Table A-2), and the sense strand comprises a nucleobase sequence containing any one of SEQ ID NO: 29-49 or 154-208 (i.e., any one of the sense strand sequences in Table 1B or Table A-2). Such siRNA may further comprise at least one ligand attached to the 5' or 3' end of either the antisense or sense strand, or any combination thereof, wherein each ligand is independently selected from the group consisting of: GalNAc moieties, C16 lipids, and C18 lipids.
[0218] One embodiment is an siRNA containing an antisense strand, said antisense strand comprising any one of SEQ ID NO: 50-153 or 209-327.
[0219] One embodiment is an siRNA comprising a sense strand, said sense strand comprising any one of SEQ ID NO: 29-49 or 154-208.
[0220] One embodiment is an siRNA comprising the sense / antisense pair detailed in Table 1B or Table A-2. Such siRNA may also comprise at least one ligand attached to the 5' or 3' end of either the antisense or sense strand, or any combination thereof, wherein each ligand is independently selected from the group consisting of: GalNac moieties, C16 lipids, and C18 lipids.
[0221] One embodiment is a bistrand of Table 1B or A-2, wherein the positive strand of the bistrand contains a ligand at its 5' end, wherein the ligand is selected from the group consisting of: GalNAc moieties, C16 lipids, and C18 lipids.
[0222] One embodiment is an siRNA comprising the positive strand sequence of SEQ ID NO: 32, or a sequence that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 32.
[0223] One embodiment is an siRNA comprising the antisense strand sequence of SEQ ID NO: 75, or a sequence that is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 75.
[0224] One embodiment is an siRNA comprising the positive strand sequence of SEQ ID NO: 32, or at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 32, and the antisense strand sequence of SEQ ID NO: 75, or at least 80%, 85%, 90%, or 95% identical to SEQ ID NO: 75. Such siRNA may comprise a ligand attached to the 5' end of the positive strand, wherein the ligand is selected from the group consisting of GalNAc moieties, C16 lipids, and C18 lipids. In some embodiments, such ligands may be attached via a C6 amine linker.
[0225] One implementation plan is as follows Figure 4 The siRNA described in the text.
[0226] One embodiment is an siRNA comprising an antisense strand having the modification pattern detailed in Table 2A or 2B, and the siRNA targeting the C3 transcript. Such siRNA may also comprise a sense strand having the modification pattern detailed in Table 3A or 3B. Such siRNA may further comprise at least one ligand attached to the 5' or 3' end, or any combination thereof, of either the antisense or sense strand, wherein each ligand is independently selected from the group consisting of: GalNac moieties, C16 lipids, and C18 lipids. Such siRNA may comprise the antisense strand nucleotide sequence detailed in Tables 1A, 1B, A-1, or A-2. Such siRNA may also comprise the sense strand nucleotide sequence detailed in Tables 1A, 1B, A-1, or A-2.
[0227] One embodiment is a method of treating a subject who has or is at risk of complement-mediated disease, the method comprising administering to the subject a composition containing an effective amount of the siRNA described herein. Such a method includes reducing the level of C3 transcripts or C3 protein in the subject or a biological sample from the subject relative to the level prior to administration of the siRNA. For example, the level of C3 transcripts or C3 protein relative to the level prior to administration of the siRNA may be reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater. The siRNA may be administered to the subject intravenously or subcutaneously. In some embodiments, the siRNA is administered to the subject's hepatocytes (e.g., ex vivo or in vivo). The subject may be administered a second agent, such as an anti-C3 antibody or a compstatin analogue.
[0228] One embodiment is a composition comprising the siRNA detailed herein, as well as a carrier and / or excipient.
[0229] One embodiment is a method for reducing or inhibiting complement C3 expression in cells, the method comprising contacting the cells with an siRNA detailed herein. Such a method includes reducing the level of C3 transcripts or C3 protein in the cells relative to the level prior to siRNA administration. For example, the level of C3 transcripts or C3 protein relative to the level prior to siRNA administration may be reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater. In some embodiments, the cells are in a subject (e.g., a human subject). In some embodiments, the subject suffers from a complement-mediated condition.
[0230] Example The present disclosure is further illustrated by the following examples. These examples are provided for illustrative purposes only and should not be construed as limiting the scope or content of the present disclosure in any way.
[0231] Example 1: Knockdown of C3 expression in HepG2 cells using siRNA The double-stranded pairs from Table 1B were tested.
[0232] Cell culture HepG2 cells were obtained from ATCC (ATCC in collaboration with LGC Standards, Wessel, Germany, catalog number #ATCC-HB-8065) and cultured in a humidified incubator at 37°C in a 5% CO2 atmosphere in a MEM Eagle (#M2279, Sigma-Aldrich, Germany) supplemented with 10% fetal bovine serum (#1248D, Biochrom GmbH, Berlin, Germany), 1× non-essential amino acids (#K0293; Biochrom, Berlin, Germany), 4 mM L-glutamine (#K0283, Biochrom, Berlin, Germany) and 100 U / ml penicillin / 100 μg / ml streptomycin (#A2213, Biochrom GmbH, Berlin, Germany).
[0233] siRNA As detailed in Table 1B, siRNA was designed and synthesized.
[0234] Dose response experiment siRNA transfection was performed using Lipofectamine RNAiMax (Invitrogen / Life Technologies, Karlsruhe, Germany) according to the manufacturer's instructions for reverse transfection.
[0235] Each siRNA was tested in HepG2 cells using a dose-response assay (DRC). The DRC was performed with siRNA at 10 concentrations, quadruple transfection, starting at 100 nM and decreasing to approximately 10 fM in a 6-fold dilution step. Simulated transfected cells served as negative controls.
[0236] For each well, the target mRNA level was normalized relative to the corresponding GAPDH mRNA level. The activity of a given siRNA is expressed as a percentage of the corresponding target mRNA concentration in treated cells (normalized to GAPDH mRNA), relative to the average target mRNA concentration (normalized to GAPDH mRNA) in the simulated transfection wells (DRC). IC20, IC50, IC80 values and Max KD from the DRC experiments are shown in Table A-1 below. The sequences of these siRNAs are shown in Table 1B above.
[0237] The IC50 and IC80 values in Table A-1 indicate that these modification modes differ in performance. (N / M in Table A stands for "Not Measured".) Table A-1 Example 2: Knockdown of C3 expression in HepG2 cells using siRNA The double-stranded pairs were tested.
[0238] Cell culture HepG2 cells were obtained from ATCC (ATCC in collaboration with LGC Standards, Wessel, Germany, catalog number #ATCC-HB-8065) and cultured in a humidified incubator at 37°C in a 5% CO2 atmosphere in MEM Eagle (#M2279, Sigma-Aldrich, Germany), supplemented with 10% fetal bovine serum (#1248D, Biochrom GmbH, Berlin, Germany), 1× non-essential amino acids (#K0293; Biochrom, Berlin, Germany), 4 mM L-glutamine (#K0283, Biochrom, Berlin, Germany) and 100 U / ml penicillin / 100 μg / ml streptomycin (#A2213, Biochrom GmbH, Berlin, Germany).
[0239] siRNA siRNAs were designed and synthesized with the sequences and modification patterns detailed in this paper.
[0240] experiment siRNA transfection was performed using Lipofectamine RNAiMax (Invitrogen / Life Technologies, Karlsruhe, Germany) according to the manufacturer's instructions for reverse transfection.
[0241] The siRNAs detailed in Table A-2 below were tested in HepG2 cells.
[0242] Two concentrations of siRNA were used: 10 nM and 0.1 nM.
[0243] For each well, the target mRNA level was normalized relative to the corresponding GAPDH mRNA level. The activity of a given siRNA is expressed as the percentage mRNA concentration of the corresponding target in the treated cells (normalized to GAPDH mRNA), relative to the average target mRNA concentration (normalized to GAPDH mRNA) in the simulated transfection wells.
[0244] In further experiments, a group of potent siRNAs derived from the HepG2 assay were synthesized using GalNAc conjugates, and their activity was evaluated in a free uptake study of primary human hepatocytes. Exemplary dose-response activity curves of the conjugated siRNAs are shown in [Figure / Image / Insert Image ... Figure 1A middle.
[0245] In further experiments, primary human astrocytes were treated with TNF-α to stimulate C3 gene expression, and then exemplary siRNAs were transfected into the cells and their efficacy was evaluated. Figure 1B The dose-response activity curves of exemplary conjugated siRNAs in primary human astrocytes are shown.
[0246] In further in vitro experiments, the ability of the exemplary siRNA from this embodiment to stimulate the expression of IP-10 and MIP-1α in hPBMCs from three donors was evaluated. Figure 2 Heatmap data illustrating the immunostimulatory potential of exemplary siRNAs in a human PBMC transfection assay are shown. Positive and negative controls were used to validate the functionality of the assay and ensure normal responsiveness of donor cells. Regarding Table A-2, lowercase letters a, c, g, or u refer to nucleotides modified with 2'O-methyl (2'OMe). Uppercase letters followed by 'f' refer to nucleotides modified with 2'F. Uppercase letters A, C, G, or U, without any other characters, refer to unmodified ribonucleotides. When 's' appears between two letters, it refers to a 3' phosphate thioester bond between the nucleotide preceding and following the 's'. When 'ps' appears at the 5' end of the sequence, the 'ps' represents a 5' phosphate thioester group on the first 5' nucleotide. The abbreviation X-GNA refers to a glycerol nucleic acid containing the nucleotide base "X"—for example, "U-GNA" refers to a glycerol nucleic acid with a uracil nucleotide base. The abbreviation "Xo" refers to an unlocked nucleic acid containing the nucleotide base "X"—for example, Uo refers to an unlocked nucleic acid with a uracil nucleotide base. The abbreviation "(vinu)" refers to a uracil nucleotide with a 2'OMe modification on the sugar and a 5'... (E) Nucleotides of vinylphosphonates. The abbreviation "Xm" refers to a nucleotide with an "X" nucleotide base and a sugar modified with 2'-O-methoxyethyl—for example, "Gm" refers to a nucleotide with guanine as the nucleotide base and a sugar modified with 2'-O-methoxyethyl. The abbreviation "Bn-X" refers to a nucleotide with an "X" nucleotide base and a sugar modified with 2'-O-benzyl—for example, "Bn-G" refers to a nucleotide with guanine as the nucleotide base and a sugar modified with 2'-O-benzyl. The abbreviation "isodX" refers to isoguanine or isocytosine nucleotides, as shown—for example, "isodG" refers to isoguanine nucleotides.
[0247] Example 3: Evaluation of siRNA administered intrathecally in NHP.
[0248] Non-primiparous cynomolgus monkeys were implanted with an intrathecal catheter as part of a previous study. On days 1 and 43 of the study, artificial cerebrospinal fluid (aCSF) or a C16 fatty acid-conjugated siRNA selected from Examples 1 or 2 was administered to the animals via lumbar puncture. Throughout the in vivo study, CSF was collected via the catheter, and animals were sacrificed 6 weeks (day 85) after the final dose. Data in Figure 3 are derived from siRNA duplex 28A. Evaluation was performed by immunoassay. Figure 3A CSF and ( Figure 3B C3 protein levels in plasma. C3 gene expression levels in CNS tissues and liver were analyzed by RT-qPCR and normalized to those of vector-treated animals. Figure 3C The exposure level of C16-conjugated siRNA antisense strand (AS) was quantified using LC-MS / MS. Figure 3D Following two L-IT doses, C16-conjugated siRNA AS showed CSF exposure ( Figure 3E These studies highlight the discovery of a potent C3-targeting siRNA with silencing activity in Alzheimer's disease-associated brain regions in NHP. Further research indicates that the C16-conjugated siRNA is non-immunostimulatory and tolerable in NHP.
[0249] Equivalent solution Those skilled in the art will recognize or be able to determine many equivalent embodiments of the invention described herein using only conventional experiments. The scope of the invention is not intended to be limited to the foregoing description, but rather as set forth in the following claims.
Claims
1. A separate, modified sequence comprising any one of SEQ ID NO: 15-28.
2. A separate, modified sequence comprising any one of SEQ ID NO: 1-14.
3. The isolated, modified sequence as claimed in claim 1 or 2, further comprising at least one ligand attached to the 5' or 3' end of the sequence.
4. An siRNA comprising an antisense strand and a sense strand, wherein the antisense strand comprises a nucleotide sequence containing any one of SEQ ID NO: 15-28, and the sense strand comprises a nucleotide sequence containing any one of SEQ ID NO: 1-14.
5. The siRNA of claim 4, further comprising at least one ligand attached to the 5' or 3' end of the antisense strand or the sense strand.
6. The siRNA of claim 5, wherein the ligand comprises at least one GalNAc moiety.
7. The siRNA of claim 5, wherein the ligand comprises an oleic acid moiety.
8. An siRNA comprising an antisense strand, said antisense strand comprising any one of SEQ ID NO: 15-28 and 50-153.
9. An siRNA comprising a sense strand, said sense strand comprising any one of SEQ ID NO: 1-14 and 29-47.
10. An siRNA, wherein the siRNA comprises a sense / antisense pair as detailed in Table 1A, Table 1B, Table A-1 or Table A-2.
11. The siRNA of claim 10, further comprising at least one ligand attached to the 5' or 3' end of the antisense strand or the sense strand.
12. The siRNA of claim 11, wherein the ligand comprises at least one GalNAc moiety.
13. The siRNA of claim 11, wherein the ligand comprises an oleic acid moiety or a C16 moiety.
14. An siRNA comprising an antisense strand and a sense strand, wherein the antisense strand comprises a modification pattern detailed in Table 2A or Table 2B, and the siRNA targets the C3 transcript.
15. The siRNA of claim 14, wherein the sense strand has the modification pattern detailed in Table 3A or Table 3B.
16. The siRNA of claim 14 or 15, further comprising at least one ligand attached to the 5' end of the sense strand, the 3' end of the sense strand, the 5' end of the antisense strand, the 3' end of the antisense strand, or a combination thereof.
17. The siRNA of claim 16, wherein the ligand comprises at least one GalNAc moiety.
18. The siRNA of claim 16, wherein the ligand comprises three GalNAc moieties.
19. The siRNA of claim 16, wherein the ligand comprises an oleic acid moiety.
20. The siRNA according to any one of claims 14-19, wherein the siRNA has the antisense strand nucleobase sequence detailed in Table 1A or Table A-1.
21. The siRNA according to any one of claims 14-20, wherein the siRNA has the positive strand nucleobase sequence detailed in Table 1A or Table A-1.
22. A method of treating a subject suffering from or at risk of complement-mediated disease, the method comprising administering to the subject a composition comprising an effective amount of siRNA as described in any one of claims 4-21, 47 or 48.
23. The method of claim 22, wherein after administration of the composition, the level of C3 transcripts or C3 protein in the subject or in a biological sample from the subject is reduced relative to the level before administration of the composition.
24. The method of claim 23, wherein the level of C3 transcript or C3 protein is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater relative to the level before administration.
25. The method of any one of claims 22-24, wherein the composition is administered intrathecally, intravenously, or subcutaneously to the subject.
26. The method of any one of claims 22-24, wherein the composition is administered to the liver cells of the subject.
27. The method of claim 26, wherein the composition is administered ex vivo to the hepatocytes.
28. The method of claim 26, wherein the composition is administered in vivo to the hepatocytes.
29. The method of any one of claims 22-28, further comprising administering a second agent to the subject.
30. The method of claim 29, wherein the second agent is an anti-C3 antibody or a compstatin analogue.
31. The method of any one of claims 22-30, wherein the subject has a complement regulation deficiency, optionally wherein the deficiency comprises abnormally low expression of one or more complement regulatory proteins in at least some cells of the subject.
32. The method of any one of claims 22-31, wherein the complement-mediated condition is a chronic condition.
33. The method of any one of claims 22-32, wherein the complement-mediated condition involves complement-mediated damage to erythrocytes, optionally wherein the condition is paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome.
34. The method of any one of claims 22-32, wherein the complement-mediated condition is an autoimmune disease, optionally wherein the condition is multiple sclerosis.
35. The method of any one of claims 22-32, wherein the complement-mediated condition involves the kidney, optionally wherein the condition is membranoproliferative glomerulonephritis, lupus nephritis, IgA nephropathy (IgAN), primary membranous nephropathy (primary MN), C3 glomerulonephropathy (C3G), or acute kidney injury.
36. The method of any one of claims 22-32, wherein the complement-mediated condition involves the central or peripheral nervous system or neuromuscular junction, optionally wherein the condition is neuromyelitis optica, Guillain-Barré syndrome, multifocal motor neuropathy, or myasthenia gravis.
37. A composition comprising siRNA as claimed in any one of claims 4-21, 47 or 48, and a carrier and / or excipient.
38. A method for reducing or inhibiting complement C3 expression in cells, the method comprising contacting the cells with siRNA as described in any one of claims 4-21.
39. The method of claim 38, wherein after the contact step, the level of C3 transcript or C3 protein is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater relative to the level before the contact step.
40. The method of claim 38 or 39, wherein the cells are in the subject.
41. The method of any one of claims 22-36 or 40, wherein the subject is a human being.
42. The method of claim 41, wherein the subject suffers from a complement-mediated condition.
43. A method for reducing or inhibiting the expression of C3 in a subject, the method comprising contacting the subject's cells with siRNA as described in any one of claims 4-21 or the composition as described in claim 37.
44. The method of claim 43, wherein after the contact step, the level of C3 transcript or C3 protein is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or greater relative to the level before the contact step.
45. The method of claim 43 or 44, wherein the subject is a human being.
46. The method of claim 45, wherein the subject suffers from a complement-mediated condition.
47. An siRNA comprising an antisense strand, wherein the antisense strand comprises any one of the siRNA antisense strand sequences detailed in Table 1B, Table A-1, or Table A-2.
48. An siRNA comprising a positive sense strand, wherein the positive sense strand comprises any one of the siRNA positive sense strand sequences detailed in Table 1B, Table A-1, or Table A-2.
49. The siRNA of claim 10, wherein the positive strand has the sequence of SEQ ID NO:
32.
50. The siRNA of claim 10, wherein the antisense strand has the sequence of SEQ ID NO:
75.
51. The siRNA of claim 49, wherein the siRNA has the sequence of double strands 14A-36A as shown in Table 1B.
52. The siRNA according to any one of claims 49-50, wherein the siRNA further comprises a GalNAc portion.
53. The siRNA according to any one of claims 49-50, wherein the siRNA further comprises a C16 portion.
Citation Information
Patent Citations
High affinity nucleic acid ligands of complement system proteins
US20030191084A1
5'-modified bicyclic nucleic acid analogs
US20070287831A1
TRANSDUCIBLE DELIVERY OF siRNA BY dsRNA BINDING DOMAIN FUSIONS TO PTD / CPPS
US20090093026A1
Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
US20090093425A1
Glycoconjugates of RNA Interference Agents
US20090203135A1
